Generated by All in One SEO v4.9.3, this is an llms.txt file, used by LLMs to index the site.

# DrugCard: Comprehensive Literature Screening & Pharmacovigilance Solutions

Your global partner for local literature screening

## Sitemaps

- [XML Sitemap](https://drug-card.io/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Blog](https://drug-card.io/blog/)
- [Silicone Allergy: Rare but Real](https://drug-card.io/blog/silicone-allergy-rare-but-real/) - Silicone is widely used for its versatility and compatibility with the human body. It has become an important part of modern medicine and many products we use every day. Today, medical grade silicone products have become a popular choice for implants, prosthetics, catheters, wound care, and countless other applications in healthcare. Manufacturers often describe silicone
- [Pharmacovigilance Automation: Transforming Drug Safety Processes](https://drug-card.io/blog/pharmacovigilance-automation-transforming-drug-safety-processes-drugcard/) - Pharmacovigilance automation streamlines drug safety workflows, including pharmacovigilance literature monitoring, improving efficiency, compliance and patient safety. Intro The volume of safety data generated throughout the lifecycle of marketed drugs continues to increase. Pharmaceutical companies must collect and evaluate information from clinical trials, patient reports, scientific literature, real-world evidence, and other data sources. This growing workload
- [What Is Drug Safety and Pharmacovigilance? Explained](https://drug-card.io/blog/what-is-drug-safety-and-pharmacovigilance-explained-drugcard/) - What is drug safety and pharmacovigilance? These are core concepts in the pharmaceutical industry that ensure product safety, medication safety, and patient protection throughout the entire drug lifecycle. Drug safety refers to the continuous evaluation of a medicine’s safety from early drug development through lifecycle management and real-world use. Pharmacovigilance is the scientific discipline focused
- [Real-World Evidence in Pharmacovigilance: Rethinking “Common” Side Effects](https://drug-card.io/blog/real-world-evidence-in-pharmacovigilance-rethinking-common-side-effects/) - In the prescribing information, adverse reaction rates are often taken as the definitive measure of a drug’s safety. However, these data are based on clinical trials and only tell part of the story. In real-world clinical practice, Real-World Evidence complements this knowledge, refining the safety profile and expanding understanding of risks in different patient populations.
- [Public Pharmacovigilance Databases for Drug Side Effects](https://drug-card.io/blog/public-pharmacovigilance-databases-for-drug-side-effects/) - Publicly accessible pharmacovigilance databases play a vital role in global drug safety monitoring. They collect reports of potential adverse drug reactions, helping to identify potential safety issues. This article reviews the main open databases, including VigiAccess, EudraVigilance, FDA AEMS, MedEffect Canada, and DAEN, along with their capabilities, applications, and limitations. Public Pharmacovigilance Databases and Their
- [Drug-Food Interactions in Drug Safety](https://drug-card.io/blog/how-food-and-drug-interactions-affect-drug-safety/) - In pharmacovigilance, much of the focus is placed on drug–drug interactions, adverse event reporting, and signal detection. However, one of the most common and preventable contributors to variability in drug safety often receives far less attention: the interaction between food and medications. Even ordinary foods and beverages can alter how the body absorbs, metabolises, or
- [PBRER vs PSUR: Key Differences in Pharmacovigilance](https://drug-card.io/blog/pbrer-vs-psur-key-differences-in-pharmacovigilance-drugcard/) - Understanding the differences between PBRER and PSUR is essential for global pharmacovigilance compliance, whether your organisation manages reporting internally or relies on expert PSUR services and PV literature monitoring. Intro PBRER vs PSUR is one of the most frequently discussed topics in pharmacovigilance, especially among professionals working with global safety reporting. Pharmaceutical companies are required
- [Drug abuse for weight loss](https://drug-card.io/blog/drug-abuse-for-weight-loss/) - Abuse is the persistent or sporadic intentional overuse of a drug, resulting in harmful physical or psychological effects. Like drug and alcohol addiction, abuse is not uncommon. Abuse applies not only to prescription drugs but also to over-the-counter drugs. For example, diuretics and laxatives are available at every pharmacy and are often used for weight
- [Redheads' Unique Medicines Responses](https://drug-card.io/blog/redheads-unique-medicines-responses/) - Pharmacogenomics studies how human genes influence the action of drugs in the body. Today, this field is becoming increasingly important for personalised medicine. Interestingly, redheads, who make up only 1-2% of the world's population, often have genetic traits that can influence drug metabolism, pain sensitivity, and response to anesthesia. This is why they attract the
- [Adverse Drug Reactions: What You Need to Know](https://drug-card.io/blog/adverse-drug-reactions-what-you-need-to-know/) - Adverse drug reaction (ADR) is a common phenomenon found in all drugs, from aggressive anti-cancer drugs to more safe drugs of plant origin. We should not associate ADR only with suspicion of substandard and falsified medical products. Even drugs that meet all quality standards can cause ADRs, especially if are not used in accordance with
- [Drug Safety and Pharmacovigilance](https://drug-card.io/blog/drug-safety-and-pharmacovigilance/) - The incredible scientific progress in the field of medicine and pharmacy is considered one of the greatest achievements of mankind. Today we can successfully treat many of those diseases even about which we knew almosth nothing 100 years ago. Life expectancy has increased, thanks in large part to the development of health care and new
- [First Reports On Adverse Drug Reactions](https://drug-card.io/blog/first-reports-on-adverse-drug-reactions/) - The history of pharmacovigilance is often presented as a sequence of catastrophes and deaths associated with the drugs. Risks and adverse drug reactions (ADRs) obviously accompanied patients and doctors from the beginning of medicine. Even Hippocrates instructed the ancient doctors with the principle of "primum non nocere" («first of all do no harm»). The search
- [DrugCard Pharmacovigilance Platform Received Investments - DrugCard Blog](https://drug-card.io/blog/drugcard-pharmacovigilance-platform-received-investments/) - The DrugCard Pharmacovigilance Platform is a solution for automatic monitoring of medical literature to help pharmaceutical companies reduce costs, optimize routine processes and ensure compliance with regulatory requirements in pharmacovigilance. In November 2021, the DrugCard team closed an investment round of €255,000. The main investors are the leader of the Ukrainian pharmaceutical market “Farmak” and
- [DrugCard Updates / January 2022 - DrugCard Blog](https://drug-card.io/blog/drugcard-updates-january-2022/) - DrugCard is an electronic pharmacovigilance platform that effectively automates routine processes, including the monitoring of literature for adverse drug reactions (ADRs). In this post we present the DrugCard Updates, implemented in January 2022. We have significantly expanded the list of local scientific and medical literature sources for regular monitoring. Now, along with journals from Ukraine,
- [Detection of New Safety Signals in Pharmacovigilance - DrugCard Blog](https://drug-card.io/blog/detection-of-new-safety-signals-in-pharmacovigilance/) - The detection and evaluation of new drug safety signals is a routine task in pharmacovigilance. Nevertheless, both guidelines: EU GVP and UA Guideline on good pharmacovigilance practices of the Ministry of Health of Ukraine 42-8.7:2018 take this process to the category of critical. Therefore, it is necessary to understand what to consider the signal and how to
- [Pharmacovigilance in Wartime](https://drug-card.io/blog/pharmacovigilance-in-wartime/) - Pharmacovigilance should be continuous. This rule runs through all regulations. MAHs and competent authorities must continuously monitor medicinal products for any new information available and evaluate its impact on the risk/benefit ratio. Companies establish risk-based business continuity plans for this purpose. Such plans include emergency measures and backup systems for the exchange of urgent information
- [Special Patient Populations in Pharmacovigilance: Practical Cases - DrugCard Blog](https://drug-card.io/blog/special-patient-populations-in-pharmacovigilance-practical-cases/) - Monitoring of safety information by pharmaceutical companies is sometimes carried out only to collect case safety reports. At the same time, special patient populations are essential for tracking the use of drugs (children, elderly, pregnant, etc.). The possible effects of the drug on the fetus should also be monitored. It helps to determine the outcome
- [Monitoring the Use of Glucocorticosteroids: Practical Cases](https://drug-card.io/blog/monitoring-the-use-of-glucocorticosteroids-practical-cases/) - It is not easy to imagine modern clinical practice without the use of systemic glucocorticosteroids (GCs). Patients often see a rapid positive effect from systemic corticosteroids, significantly prolonged action. And it results in extended and uncontrolled use of these drugs. As a result, such experiments often lead to many ADRs. Patients frequently develop Cushing syndrome,
- [Identifying Risk Factors for Drug Use](https://drug-card.io/blog/identifying-risk-factors-for-drug-use/) - Drug therapy aims to achieve the best possible benefit/harm balance of treatment. The basis of this adapted therapy is identifying and characterising risk factors of adverse drug reactions (ADR). Many aspects can increase the number of ADRs. Hereditary factors make some people more susceptible to the toxic effects of certain drugs. Associated diseases can alter
- [New Indications for Drug Use](https://drug-card.io/blog/new-indications-for-drug-use/) - In medical literature, pharmacovigilance specialists find new information on drug effectiveness and drug safety. The literature is one of the primary data sources on drug use experience in real clinical practice (Real-world data (RWD) and Real-world evidence (RWE)). We should note that RWD and RWE play an increasingly important role in health decision-making. Thus, the
- [Cannabis Effects on Medicines](https://drug-card.io/blog/cannabis-effects-on-medicines/) - Recently, the Ministry of Health of Ukraine reported on the Government’s support of the draft bill regulating hemp plant (Cannabis) circulation. It applies to medical, scientific and technological activities. As noted by the Ministry of Health, medical cannabis can prevent patient suffering and improve the treatment of more than 50 conditions. The bill will thus
- [Adverse drug reactions in medical literature](https://drug-card.io/blog/adverse-drug-reactions-in-medical-literature/) - Marketing Authorisation Holders (MAH) should report to competent authorities (CA) adverse drug reactions received spontaneously or identified from the literature. Both sources of information are important for evaluating drug safety. Safety cases from the medical literature may have clinical significance, especially for rare events. Because they may not be detected in clinical trials prior to
- [Rare Сases of Adverse Reactions](https://drug-card.io/blog/rare-sases-of-adverse-reactions/) - The amount of scientific and medical literature pharmaceutical companies must monitor is increasing yearly. Therefore, the DrugCard platform constantly adds new relevant literature sources for screening. This list of sources contains specialised medical literature from Europe, Ukraine and CIS countries. It also includes websites of local and global regulatory authorities (EMA, WHO, FDA, MHRA, TGA
- [Classical and atypical Reye’s syndrome](https://drug-card.io/blog/classical-and-atypical-reyes-syndrome/) - Reye’s syndrome is a rare and potentially fatal pediatric illness defined as acute noninflammatory encephalopathy with fatty liver failure. Australian pathologist R.D.K. Reye first described this syndrome in 1963. Reye's syndrome usually manifests in children in the form of vomiting and confusion with rapid progression to coma and death. This syndrome often begins in the
- [DrugCard Updates / 2022 Mid-Year](https://drug-card.io/blog/drugcard-updates-2022-first-half-year/) - DrugCard is an electronic pharmacovigilance platform that automates routine processes, including literature monitoring to search for information on drug safety. Updating literature monitoring sources, adding literature from new countries and significantly improving the functionality of the DrugCard platform. This is something we are constantly and persistently working on in order to meet all the requirements
- [In-flight hypoglycemia](https://drug-card.io/blog/in-flight-hypoglycemia/) - Diabetes mellitus is one of the most common chronic health conditions around the world. According to WHO, the number of adults living with diabetes has almost quadrupled to 422 million adults since 1980. More than 95% of people with diabetes have type 2 diabetes. Lowering blood glucose levels through lifestyle modifications and glucose-lowering medications is
- [Paracetamol overdose](https://drug-card.io/blog/paracetamol-overdose/) - Acute liver failure is loss of liver function that occurs rapidly often in a person with no preexisting liver disease. It's most commonly caused by viral hepatitis or drugs, such as paracetamol (acetaminophen). Paracetamol is one of the most commonly used oral analgesics and antipyretics. It has an excellent safety profile when administered in proper
- [Local medical literature of Kazakhstan](https://drug-card.io/blog/local-medical-literature-of-kazakhstan/) - The medical literature is an important source of information for the identification of adverse drug reactions. MAHs are required to monitor local scientific and medical publications in countries where they obtain marketing authorizations. But some companies do not pay much attention to monitoring local literature. They are under the impression that drug safety information could
- [Patient safety and SmPC update](https://drug-card.io/blog/patient-safety-and-smpc-update/) - The Summary of Product Characteristics (SmPC) is the main document that contains key information for healthcare professionals and patients about the safety and efficacy of a medicinal product. The safety profile of any drug may change throughout its life cycle as new safety information becomes available. Therefore, the SmPCs should be regularly reviewed and updated
- [Contrast agents may cause serious reactions: clinical cases](https://drug-card.io/blog/contrast-agents-may-cause-serious-reactions-clinical-cases/) - Various forms of contrast media are used to improve medical imaging. For patients undergoing radiographic imaging like x-rays or computed tomography (CT) scans, contrast agents either iodine (ICM) or barium-based are used. For magnetic resonance imaging (MRI), most contrast agents are based on chelated gadolinium. The use of contrast agents has become common in recent
- [Topical steroids may harm the eyes](https://drug-card.io/blog/topical-steroids-may-harm-the-eyes/) - Steroids are one of the most commonly prescribed drugs, used mainly to treat various autoimmune and inflammatory conditions. Although they do have numerous benefits, steroid usage can cause many adverse effects as well. The most important effects affecting the eyes are steroid-induced glaucoma and cataracts. Steroid-induced iatrogenic glaucoma was described for the first time in
- [DrugCard Updates / August 2022](https://drug-card.io/blog/drugcard-updates-august-2022/) - August has been very fruitful for the DrugCard team. We have not only expanded the literature sources for monitoring but also introduced a new grand functionality of the platform. Just half an hour after deploying the new features, we received the first positive feedback from our clients. In this publication, we present the DrugCard Updates,
- [Antidepressants increase the risk of child development disorders](https://drug-card.io/blog/antidepressants-increase-the-risk-of-child-development-disorders/) - Pregnancy and antidepressants The safety of taking antidepressants during pregnancy is still a topic of debate and new research. The main thing in the context of this issue is to determine which risks are more dangerous: using antidepressants or the consequences of depression without treatment. Since pregnancy provokes a variety of hormonal changes, in some
- [Customer use case. How Pharma companies improve MLM process](https://drug-card.io/blog/customer-use-case-how-pharma-companies-improve-mlm-process/) - Pharmacovigilance, being related to drug safety, is one of the key processes for any pharmaceutical company. Good pharmacovigilance practices (GVP) guidelines and legal requirements strictly regulate all pharmacovigilance activities. Drug manufacturers must constantly monitor scientific publications in specialized medical journals to obtain information on the safety and effectiveness of the registered drug use, both globally
- [Intriguing side effects of capecitabine](https://drug-card.io/blog/intriguing-side-effects-of-capecitabine/) - Capecitabine is a type of chemotherapy. It is used as a treatment for different types of cancer, including bowel cancer. The body changes capecitabine into a common chemotherapy drug called fluorouracil. Cancer cells need to make and repair DNA to grow and multiply. Capecitabine stops cells from making and repairing DNA. Since the growth of normal
- [An unusual side effect of anticoagulants](https://drug-card.io/blog/an-unusual-side-effect-of-anticoagulants/) - Anticoagulants are amongst the most commonly prescribed medications worldwide. Anticoagulants are used to prevent blood clots in blood vessels. Blood clots can block blood vessels (an artery or a vein). These medications can help stop life-threatening conditions like strokes, heart attacks, and pulmonary embolisms, all of which can happen because of blood clots. Obviously, the
- [Highlight your search keywords for MLM](https://drug-card.io/blog/highlight-your-search-keywords-for-mlm/) - Safe and effective use of medicines is a crucial objective of pharmacovigilance. Published medical literature is a well-recognized and valuable source of information about pharmaceutical products. Important data about new types of adverse drug reactions may first appear as published individual case reports. Literature monitoring includes published articles and reviews in indexed or non-indexed journals,
- [Propofol - "Milk of anesthesia"](https://drug-card.io/blog/propofol-milk-of-anesthesia/) - Propofol, commonly called the "milk of anesthesia," is one of the modern most popular intravenous anesthetic agents. Propofol has many pharmacological advantages over other anesthetic agents i.e. rapid, short action and fewer side effects. Its anesthetic properties were first reported in January 1973. In 1986 propofol was introduced for therapeutic use as a lipid emulsion
- [Vaccines against COVID-19 and literature monitoring](https://drug-card.io/blog/vaccines-against-covid-19-and-literature-monitoring/) - Vaccination is one of the important achievements in public health. All medicines, including vaccines, have benefits and risks. Safety monitoring after approval is important to quickly identify any new or changing risks and take action. Of course, this also applies to vaccines against coronavirus disease. Unprecedented scientific collaborations have allowed COVID-19 vaccine research, development, and
- [Antibiotic safety is not only antibiotic resistance](https://drug-card.io/blog/antibiotic-safety-is-not-only-antibiotic-resistance/) - Antibiotic resistance is one of our most significant public health challenges. But we should not forget other safety problems of the use of antibiotics. Why this is so, we will tell on the example of the well-known antibiotic piperacillin-tazobactam. Broad-spectrum antibiotics, such as piperacillin-tazobactam (PTZ), play an essential role in the empirical therapy of serious infections.
- [A rare and unpredictable reaction](https://drug-card.io/blog/a-rare-and-unpredictable-reaction/) - Stevens-Johnson syndrome (SJS) is a serious skin reaction usually caused by certain medicines. It's usually a reaction to medication that starts with flu-like symptoms, followed by a painful rash that spreads. Then the top layer of affected skin dies, sheds, and begins to heal after several days. Stevens-Johnson syndrome is a rare and unpredictable reaction. Annual incidence
- [Climate change and inhalation anesthetics](https://drug-card.io/blog/climate-change-and-inhalation-anesthetics/) - Inhaled anesthetics have been in clinical use since 1844. Their discovery was a landmark as the first form of general anesthesia. Over the years, improved inhaled anesthetics were developed and implemented in clinical practice, while older drugs were abandoned due to toxic effects. Currently, the most commonly used inhaled anesthetic agents are sevoflurane, desflurane, isoflurane
- [Article workflow improved](https://drug-card.io/blog/article-workflow-improved/) - You already know that working with the DrugCard electronic pharmacovigilance platform for literature monitoring is as easy as 1-2-3. The DrugCard platform team is constantly working on improvements to comply with GVP and GMP requirements fully. At the same time, we make the literature monitoring process as convenient as possible for our clients. Pharmacovigilance specialists
- [When DRESS is not about clothes](https://drug-card.io/blog/when-dress-is-not-about-clothes/) - The DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) syndrome encompasses drug rash with organ impairment. It was first described in 1996 by Callot et al. in a study of 21 patients with acute organ disease, eosinophilia and skin symptoms. The frequency of DRESS is estimated to be between 1/1,000 and 1/10,000 patients. Although this frequency may well be
- [Detective cases of adverse reactions](https://drug-card.io/blog/detective-cases-of-adverse-reactions/) - Often, physicians are like detectives, following clues and putting together observations to find out what happened to the patient. Of course, scientific publications are the best place where doctors can share clinical cases with their colleagues worldwide. Therefore, the medical literature is full of interesting, exciting cases in patients, including adverse reactions. Sometimes, such cases
- [Detecting serious ADRs in the medical literature](https://drug-card.io/blog/detecting-serious-adrs-in-the-medical-literature/) - Adverse drug reactions (ADRs) substantially threaten public health and patient safety. Of course, most ADRs are mild to moderate, resulting in no significant harm to patients. But, the proportion of serious ADRs, including life-threatening events and death, is not negligible. The European Medicines Agency qualifies an adverse event as serious if it: results in death is life-threatening
- [An adverse reaction with an unclear prognosis](https://drug-card.io/blog/an-adverse-reaction-with-an-unclear-prognosis/) - Neapolitan physician Carlo Curzi originally described scleroderma in a monograph dated 1752. The term is derived from the Greek words "sklerosis," meaning hardness, and "derma," meaning skin. Systemic sclerosis prevalence is estimated between 3 and 24 per 100,000 persons. The prognosis in systemic sclerosis is poor and often fatal, with 10-year survival ranging from 54–66%.
- [Enhancing the reporting of adverse drug reactions in medical journals. Part 1](https://drug-card.io/blog/enhancing-the-reporting-of-adverse-drug-reactions-in-medical-journals-part-1/) - Publication of adverse drug reactions (ADRs) reports it represents an essential part of postmarketing safety surveillance of drugs. When properly documented, reports of one or more ADR can help to alert clinicians to these possible effects. Adverse event case reports typically originate with healthcare professionals who, while caring for patients, suspect a potentially causal relationship between a medical
- [Two rare side effects of Mesalamine](https://drug-card.io/blog/two-rare-side-effects-of-mesalamine/) - Inflammatory bowel disease (IBD) is characterized by chronic recurrent gastrointestinal inflammation, including ulcerative colitis and Crohn's disease. Medical treatment for IBD has two main goals: remission and maintaining remission. Aminosalicylate (5-ASA) drugs are one treatment class used to manage mild to moderate IBD. The most commonly used medicine is mesalamine. Also, high rates of induction
- [Eliminate language barriers in pharmacovigilance](https://drug-card.io/blog/eliminate-language-barriers-in-pharmacovigilance/) - Accurate and complete information on drug safety is crucial for pharmacovigilance activities. Translation handling is essential in ensuring access to such information from different regions and populations, especially in areas where English is not the primary language. The use of human translation, machine translation, or hybrid translation depends on the type of information that needs to
- [Enhancing the reporting of adverse drug reactions in medical journals. Part 2](https://drug-card.io/blog/enhancing-the-reporting-of-adverse-drug-reactions-in-medical-journals-part-2/) - In recent years, the quantity of biomedical articles written by scientists worldwide has grown significantly. Healthcare professionals are eager to publish their scientific discoveries, particularly new, rare, or unexpected adverse drug reactions (ADRs), in certain journals within the scientific community. An initial publication of a well-documented ADR report can inspire other readers to report similar
- [Top 5 Benefits of Automating Medical Literature Screening](https://drug-card.io/blog/top-5-benefits-of-automating-medical-literature-screening/) - Literature monitoring can be a time-consuming process, which can lead to an overwhelming workload for pharmacovigilance professionals. However, using advanced technology, such as automated search algorithms, can help reduce the workload associated with literature monitoring. In particular, automating medical literature screening in pharmacovigilance can significantly benefit drug safety reporting. So, we present the top 5 benefits
- [How to Conduct a Pharmacovigilance Risk Assessment](https://drug-card.io/blog/how-to-conduct-a-pharmacovigilance-risk-assessment/) - Medication is one of the most powerful tools available for preventing and treating disease and alleviating symptoms. However, all medicines can cause adverse drug reactions (ADRs) despite their benefits. ADRs are harmful and unintended effects of drugs that occur at doses used in humans for prevention, diagnosis, or treatment. Due to their small sample size,
- [The Advantages of Cloud-Based Medical Literature Screening](https://drug-card.io/blog/the-advantages-of-cloud-based-medical-literature-screening/) - In recent years, pharmacovigilance has become a critical aspect of ensuring patient safety in healthcare. One key element of pharmacovigilance is screening medical literature to identify potential adverse drug reactions (ADRs) and other safety concerns associated with medications. With the advancement of technology, cloud-based screening has emerged as a valuable tool in enhancing pharmacovigilance efforts.
- [Saving Lives and Wallets: The Economic Role of Pharmacovigilance in Patient Safety](https://drug-card.io/blog/saving-lives-and-wallets-the-economic-role-of-pharmacovigilance-in-patient-safety/) - Recently, more and more people are acknowledging the economic benefits of pharmacovigilance. This includes its ability to save lives and cut down healthcare costs. So, our article, "Saving Lives and Wallets: The Economic Role of Pharmacovigilance in Patient Safety," aims to enlighten readers about these advantages and their growing recognition. The article aims to increase
- [Examining the Significance of Drug Safety Recalls on Pharmaceutical Companies](https://drug-card.io/blog/examining-the-significance-of-drug-safety-recalls-on-pharmaceutical-companies/) - Pharmaceutical companies hold a crucial position in society, contributing to public health through the development and distribution of medications. Nevertheless, drug safety recalls profoundly affect pharmaceutical companies and the broader healthcare ecosystem. This article explores the impact of drug safety recalls on pharmaceutical companies. It highlights their effects on reputation, financial performance, regulatory compliance, and
- [Patient-Centric Pharmacovigilance: Enhancing Trust, Patient Satisfaction, and Brand Loyalty](https://drug-card.io/blog/patient-centric-pharmacovigilance-enhancing-trust-patient-satisfaction-and-brand-loyalty/) - Patient-centricity has become a cornerstone of successful pharmaceutical companies in the rapidly evolving healthcare landscape. Focusing on patients' needs, experiences, and perspectives is essential for building trust, enhancing patient satisfaction, and fostering brand loyalty. One critical aspect of patient-centricity in healthcare is pharmacovigilance. Traditionally, pharmacovigilance has primarily revolved around regulatory compliance and post-marketing safety surveillance.
- [Revealing the Unseen Hazards: The Vital Significance of Pharmacovigilance in Patient Safety](https://drug-card.io/blog/revealing-the-unseen-hazards-the-vital-significance-of-pharmacovigilance-in-patient-safety/) - Pharmaceutical companies invest significantly in drug development, placing great emphasis on ensuring the safety of their products. The objective is to bring drugs to the market that undergo a thorough benefit-risk evaluation (BRE). Pharmacovigilance plays a vital role in both drug development and patient safety. By actively monitoring adverse drug reactions (ADRs) and promptly identifying
- [Shedding Light on Eye Drops Safety: The Importance of Pharmacovigilance](https://drug-card.io/blog/shedding-light-on-eye-drops-safety-the-importance-of-pharmacovigilance/) - Eye drops, commonly used for various eye conditions and ailments, may seem harmless at first glance. However, recent incidents have highlighted the potential dangers associated with these seemingly innocuous medications. With their high concentrations, topical ophthalmic medications can inadvertently enter the bloodstream and cause systemic effects. Furthermore, eye drops are often overlooked when considering medication
- [Safety of Obesity Medicines: Lessons Learned from Withdrawn Drugs](https://drug-card.io/blog/safety-of-obesity-medicines-lessons-learned-from-withdrawn-drugs/) - Obesity is a global health concern affecting millions worldwide, leading to various chronic conditions and reducing overall quality of life. To combat this epidemic, pharmaceutical companies have developed and marketed several obesity medicines. While these medications have provided hope for many individuals struggling with weight management, there have been instances where the safety of certain
- [The Connection Between COVID Vaccination and Swelling of Dermal Fillers](https://drug-card.io/blog/the-connection-between-covid-vaccination-and-swelling-of-dermal-fillers/) - Since the emergence of COVID-19, vaccination campaigns have played a vital role in combating the spread of the virus. Vaccines have been proven safe and effective in preventing severe illness and reducing hospitalizations. However, as with any medical intervention, specific rare side effects or interactions can require attention. The growing list of COVID complications is
- [New Safety Signals of Acetylsalicylic Acid: Surprising Revelations for an Established Medication](https://drug-card.io/blog/new-safety-signals-of-acetylsalicylic-acid-surprising-revelations-for-an-established-medication/) - According to GVP, the signal is information on a new or known adverse event potentially caused by medicine that warrants further investigation. Signals are generated from several sources, such as spontaneous reports, clinical studies, and scientific literature. It's crucial to note that safety signals can arise long after a drug has been approved and widely
- [Pharmacovigilance as a Strategic Asset: Leveraging Safety Data for Competitive Advantage](https://drug-card.io/blog/pharmacovigilance-as-a-strategic-asset-leveraging-safety-data-for-competitive-advantage/) - Pharmacovigilance is an essential part of running for all pharmaceutical companies. Many executives previously considered it a "cost center" and non-strategic. However, the perception has shifted in recent years as product safety has emerged as a critical concern, impacting a company's ability to keep products on the market and avoid significant liabilities. Historically seen as
- [Synergizing Human Insight and Machine Learning for Enhanced Pharmacovigilance Literature Monitoring](https://drug-card.io/blog/synergizing-human-insight-and-machine-learning-for-enhanced-pharmacovigilance-literature-monitoring/) - Patient safety and drug efficacy are paramount concerns in the dynamic realm of pharmacovigilance. A novel era of vigilance arises from fusing machine learning and human expertise. An essential facet of this partnership is the surveillance of medical literature for adverse events, drug interactions, and emerging safety issues. This article delves into the dynamic interplay
- [Join DrugCards at the forefront of pharmacovigilance events](https://drug-card.io/blog/join-drugcards-at-the-forefront-of-pharmacovigilance-events/) - Hello everyone, as autumn approaches, it's an exciting time for all of us in the scientific community. This autumn promises an extraordinary series of events focused on pharmacovigilance. We're delighted to announce that DrugCards actively participates in this season's key pharmacovigilance events. Save the date for an exceptional event: connect with industry leaders at the
- [Pediatric pharmacovigilance: Ensuring child safety in medical treatment](https://drug-card.io/blog/pediatric-pharmacovigilance-ensuring-child-safety-in-medical-treatment/) - Pharmacovigilance, the science of monitoring and assessing the safety of medications, is a critical component of modern healthcare. The health and well-being of children are of paramount importance in the field of medicine. Pediatric pharmacovigilance, a specialized branch of pharmacovigilance, focuses on monitoring the safety of medications administered to children. As children's bodies are unique
- [Time efficiency in pharmacovigilance](https://drug-card.io/blog/time-efficiency-in-pharmacovigilance/) - Pharmaceutical companies are continuously keeping a close watch on the safety and effectiveness of their drugs, with a primary focus on time efficiency in pharmacovigilance (PV). They do so to ensure they work well for patients while minimizing adverse side effects. Drug safety has changed significantly in the last century because of new technology, methods,
- [Understanding the role of pharmacovigilance in patient safety](https://drug-card.io/blog/understanding-the-role-of-pharmacovigilance-in-patient-safety/) - Patient safety initiatives aim to consistently and sustainably reduce risks, prevent avoidable harm, minimize errors, and effectively manage their consequences. A pivotal aspect of this endeavor is pharmacovigilance. Originating from the Latin words "pharma," signifying medicines, and "vigilare," connoting watchfulness or alertness. Pharmacovigilance encompasses a wide range of activities throughout the life cycle of medicinal
- [Unmasking the hidden culprits: Excipients in medicines](https://drug-card.io/blog/unmasking-the-hidden-culprits-excipients-in-medicines/) - Adverse drug reactions (ADRs) are a constant concern in the intricate pharmacovigilance world. As vigilant specialists, we diligently monitor the safety profiles of medications, meticulously cataloging the interactions between active pharmaceutical ingredients (APIs) and the human body. However, a lesser-known realm deserves our attention—the impact of excipients on patient safety. Excipients are the unsung heroes
- [Unique aspects of literature monitoring in veterinary pharmacovigilance](https://drug-card.io/blog/unique-aspects-of-literature-monitoring-in-veterinary-pharmacovigilance/) - In our interconnected world, animals serve more than just companionship. They are vital in our food production, scientific research, and ecological balance. It is a moral obligation and an essential requirement to ensure their well-being through veterinary pharmacovigilance. This field protects the health and happiness of our beloved pets and contributes to the broader mission
- [Balancing tradition and safety in herbal medicine](https://drug-card.io/blog/balancing-tradition-and-safety-in-herbal-medicine/) - Herbal medicine has been integral to human healthcare for millennia, offering a natural alternative to conventional pharmaceuticals. These botanical remedies, derived from plants and other natural sources, have gained popularity for their perceived safety and minimal side effects. While they can provide effective relief for a wide range of ailments, ensuring the safety of herbal
- [Dispelling misconceptions in pharmacovigilance](https://drug-card.io/blog/dispelling-misconceptions-in-pharmacovigilance/) - Pharmacovigilance is the unsung hero of the pharmaceutical industry. It's the meticulous detective work that goes on behind the scenes, ensuring that the drugs we rely on are safe and effective. However, like any field, pharmacovigilance is not immune to its fair share of stereotypes. In this article, we'll explore some of the most prevalent
- [Overcoming publication delays with DrugCard](https://drug-card.io/blog/overcoming-publication-delays-with-drugcard/) - In the ever-evolving pharmacovigilance landscape, swift access to the latest medical research is paramount. Addressing publication delays can be a game-changer, especially when ensuring patient safety and informed decision-making. While PubMed is a trusted resource for accessing medical journal articles, it isn't always the quickest route. This article delves into how the automated pharmacovigilance platform
- [Unlocking new horizons: The power of pharmacovigilance in drug repurposing](https://drug-card.io/blog/unlocking-new-horizons-the-power-of-pharmacovigilance-in-drug-repurposing/) - In the fast-paced world of pharmaceuticals, the quest to discover new drugs often steals the spotlight. However, there's a hidden gem within the industry, an uncharted territory teeming with potential – the art of drug repurposing. This practice involves finding new therapeutic uses for existing drugs. In this article, we will explore how pharmacovigilance, the
- [Antimicrobial resistance: Understanding the Domino Effect](https://drug-card.io/blog/antimicrobial-resistance-understanding-the-domino-effect/) - Antimicrobial Resistance (AMR) occurs when bacteria, viruses, fungi, and parasites stop responding to antimicrobial agents. This resistance renders antibiotics and other antimicrobial treatments ineffective, making infections challenging or impossible to treat. This situation elevates the risk of disease spread, severe illness, and death. World Antimicrobial Resistance Awareness Week (WAAW) is a global initiative to increase
- [Breathe easy: Delving into the safety of nasal drops](https://drug-card.io/blog/breathe-easy-delving-into-the-safety-of-nasal-drops/) - In a world that rarely slows down, the inconvenience of nasal congestion can disrupt even the most hectic schedules. Nasal drops have emerged as a discreet yet powerful solution, offering comfort and relief. As we embark on a journey into nasal drops, we must explore their efficacy and the importance of safety in their usage.
- [The medicinal puzzle: How medications can mimic traumatic events](https://drug-card.io/blog/the-medicinal-puzzle-how-medications-can-mimic-traumatic-events/) - In the complex world of healthcare, there's a fascinating aspect to adverse drug reactions (ADRs) when medications cause symptoms that resemble external traumas. Healthcare specialists face a challenge in figuring out whether the effects are due to the medication or actual physical harm. Let's explore this intriguing scenario where medicine intersects with mystery, and healthcare
- [Striking a balance: The vital impact of limiting drug packaging size and dosage reduction](https://drug-card.io/blog/striking-a-balance-the-vital-impact-of-limiting-drug-packaging-size-and-dosage-reduction/) - Of course, patient safety is always the top priority. One overlooked aspect that plays a crucial role in these efforts is the limitation of drug packaging sizes. Equally significant is the reduction in the dosages of released medications. Therefore, we invite you to understand the significance of establishing restrictions on the sizes and dosages of
- [Key players: Who are the stakeholders in pharmacovigilance?](https://drug-card.io/blog/key-players-who-are-the-stakeholders-in-pharmacovigilance/) - Pharmacovigilance (PV) is the art and science of keeping a close eye on the safety of medicines and making efforts to enhance their benefits while minimizing risks. It's a crucial part of public health, ensuring that medicines deliver the intended positive effects with minimal harm. As the world of pharmaceuticals constantly transforms, getting to know
- [Exploring illnesses mimicking drug side effects: The Mimicry Game](https://drug-card.io/blog/exploring-illnesses-mimicking-drug-side-effects-the-mimicry-game/) - The human body's response to illnesses and medications can sometimes present strikingly similar symptoms, leading to diagnostic puzzles for healthcare professionals. In the intricate realm of medicine, a fascinating phenomenon exists where certain illnesses mimic the symptoms of drug side effects. Termed as "medical mimicry," these conditions pose a unique challenge in diagnosis and treatment.
- [Pharmacovigilance limitations: Understanding the intricacies](https://drug-card.io/blog/pharmacovigilance-limitations-understanding-the-intricacies/) - Postmarketing surveillance relies on pharmacovigilance. It ensures that safety events related to drug use throughout its lifetime are collected, evaluated, and acted upon as necessary. This is done to ensure the ongoing safe use of medicines. At the point of market approval, a medicinal product's risks and adverse effects remain undisclosed. Therefore, postmarketing safety surveillance is
- [From Cases to Caution: Medication-Induced Gambling Behaviors](https://drug-card.io/blog/from-cases-to-caution-medication-induced-gambling-behaviors/) - The phenomenon of gambling behavior as an adverse drug reaction is associated with specific medications that impact the brain's neurotransmitter systems, particularly those influencing dopamine levels. Dopamine, a neurotransmitter tied to pleasure and reward, is crucial in decision-making and impulse control. Medications often prescribed for conditions such as Parkinson's disease (PD) or restless legs syndrome
- [Amoxicillin/clavulanic acid in focus: Uncommon complications](https://drug-card.io/blog/amoxicillin-clavulanic-acid-in-focus-uncommon-complications-explored/) - Healthcare providers worldwide commonly use Amoxicillin/clavulanic acid as an antibiotic in emergency departments and primary care offices. It is a combination of two distinct drugs: Amoxicillin and clavulanic acid. Amoxicillin, a penicillin derivative, exhibits activity against gram-positive and gram-negative bacteria. Furthermore, adding clavulanic acid broadens its spectrum to include strains producing beta-lactamase, expanding coverage to
- [Paracetamol infusion: Mitigating the risk in vulnerable populations](https://drug-card.io/blog/paracetamol-infusion-mitigating-the-risk-in-vulnerable-populations/) - Paracetamol, also known as acetaminophen, is a widely used analgesic and antipyretic medication known for its safety and efficacy. Traditionally administered orally or rectally, paracetamol has found its way into intravenous formulations, particularly in neonates, infants, and low-weight adults where precise dosing is crucial. However, the transition to paracetamol infusion raises concerns about the potential
- [Pharmacovigilance Trends: Charting the Future of Medication Safety](https://drug-card.io/blog/pharmacovigilance-trends-charting-the-future-of-medication-safety/) - Pharmacovigilance is the science of monitoring, assessing, and preventing adverse effects and other drug-related issues. It is a crucial element within the life science industry and ensures patients receive safe and effective medications. Over the years, the pharmacovigilance landscape has undergone significant changes, and this evolution is ongoing. As we navigate the intricate realm of
- [Pharmacovigilance 360: Decoding the Complexities of Drug-Induced Suicide](https://drug-card.io/blog/pharmacovigilance-360-decoding-the-complexities-of-drug-induced-suicide/) - In recent years, the association between certain medications and an increased risk of suicidal thoughts and behaviors has become a growing concern within the realm of pharmacovigilance. Drug-induced suicide (DIS) refers to cases where the use of certain medications is suspected to contribute to an individual's suicidal tendencies. Establishing this association definitively is challenging due
- [New Therapeutic Horizons: The Role of Pharmacovigilance Literature Monitoring](https://drug-card.io/blog/new-therapeutic-horizons-the-role-of-pharmacovigilance-literature-monitoring/) - The word "pharmacovigilance" originates from the Greek word "pharmakon," meaning drug, and the Latin word "vigilare," pointing to keep watch. Pharmacovigilance primarily focuses on monitoring adverse drug reactions (ADR). However, it also involves tracking the off-label use of drugs. This comprehensive approach recognizes that adverse reactions are frequently identifiable. In turn, the potential beneficial effects
- [Emphasizing Literature Surveillance in FDA’s Pharmacovigilance Requirements](https://drug-card.io/blog/emphasizing-literature-surveillance-in-fda-s-pharmacovigilance-requirements/) - Within the realm of pharmacovigilance, meeting FDA requirements is paramount for ensuring the safe and effective use of healthcare products. Moreover, regulatory bodies often consider this sector the most rigorously regulated pharmaceutical industry segment. Notably, regulators globally emphasize the importance of scientific literature in detecting risks for medicines. Neglecting or delaying literature monitoring as per
- [Drug-Induced Psoriasis Exploration Through Pharmacovigilance Lens](https://drug-card.io/blog/drug-induced-psoriasis-exploration-through-pharmacovigilance-lens/) - Psoriasis, a chronic inflammatory skin condition affecting approximately 2-3% of the global population, presents as itchy, scaly rashes primarily on the knees, elbows, trunk, and scalp. This prevalent ailment lacks a definitive cure and often leads to discomfort, sleep disturbances, and difficulty concentrating. It typically follows a pattern of recurring flare-ups lasting weeks or months,
- [The Interplay Between Sleep Disturbances and Medications](https://drug-card.io/blog/the-interplay-between-sleep-disturbances-and-medications/) - On March 15, 2024, people worldwide will celebrate World Sleep Day. In a world where sleep is often sacrificed in the pursuit of productivity, relaxation, or social engagements, the significance of quality sleep cannot be overstated. Each year, on World Sleep Day, we're reminded of the importance of healthy sleep patterns and their impact on
- [TGA and Medsafe pharmacovigilance requirements for literature monitoring](https://drug-card.io/blog/tga-and-medsafe-pharmacovigilance-requirements-for-literature-monitoring/) - Australia and New Zealand are the primary players in the pharmaceutical market within Oceania, boasting substantial industries and robust regulatory frameworks overseeing healthcare. Predictions by Statista indicate that by 2024, the pharmaceutical market in Australia & Oceania will soar to US$11.64 billion. It is projected to experience a steady annual growth rate of 6.72%, reaching
- [Fentanyl Transdermal Patches and Monitoring Safety Through Pharmacovigilance](https://drug-card.io/blog/fentanyl-transdermal-patches-and-monitoring-safety-through-pharmacovigilance/) - In the landscape of pain management, fentanyl transdermal patches have emerged as a potent solution, offering sustained relief for chronic pain sufferers. However, alongside their efficacy, concerns regarding safety and the necessity for vigilant oversight are paramount. Therefore, pharmacovigilance becomes indispensable in ensuring the benefits of these patches outweigh the potential risks. Understanding Fentanyl Transdermal
- [Modern Pharmacovigilance and Historical Events Shaping its Evolution](https://drug-card.io/blog/modern-pharmacovigilance-and-historical-events-shaping-its-evolution/) - In the modern era, while the effectiveness of drugs is paramount, their safety takes precedence. That's why ensuring drug safety transcends mere initial checks during clinical trials. It's an ongoing process extending well beyond a drug's market launch. Pharmacovigilance, centered on enhancing patient care and safety, closely monitors medication use throughout its lifecycle. Initially reactive,
- [Empowering Pharmacovigilance Professionals with DrugCard's Latest Innovations](https://drug-card.io/blog/empowering-pharmacovigilance-professionals-with-drugcard-s-latest-innovations/) - In today's rapidly changing pharmacovigilance world, staying ahead of the curve demands continual innovation and adaptability. DrugCard, a prominent platform for pharmacovigilance professionals, has recently been substantially updated. Are you familiar with the movie 'Gone in 60 Seconds'? One of our clients recently likened their experience with the DrugCard platform post-update to the pace of
- [Dexpanthenol - Basking in the Sun, Navigating the Challenge](https://drug-card.io/blog/dexpanthenol-basking-in-the-sun-navigating-the-challenge/) - As summer approaches, the temptation to soak up the sun's warmth grows. Yet, amidst the enjoyment of sunny days lies the looming threat of sunburn. Sunburn, characterized by its painful redness and inflammation, isn't merely uncomfortable - it also carries long-term risks, including premature ageing and increased susceptibility to skin cancer. Many seek relief in
- [Day 0 Decoded - EMA's New Approach to ICSRs](https://drug-card.io/blog/day-0-decoded-ema-s-new-approach-to-icsrs/) - The European Medicines Agency (EMA) recently issued a crucial update in March 2024. This update explicitly targets Marketing Authorization Holders (MAHs) to provide clarity on the concept of "Day Zero (Day 0)" concerning Individual Case Safety Reports (ICSRs) sourced from electronic and hard copy journals. Before this revision, interpretations varied, complicating matters for pharmacovigilance professionals:
- [Prescription Symmetry Sequence Analysis Unleashing Its Power in Pharmacovigilance](https://drug-card.io/blog/prescription-symmetry-sequence-analysis-unleashing-its-power-in-pharmacovigilance/) - Pharmaceutical interventions play a vital role in disease management, yet they can lead to unintended consequences known as adverse drug reactions (ADRs). Pharmacovigilance (PV) systems rely on spontaneous reporting of ADRs as a key strategy to effectively address safety concerns. This method collects real-world data from clinical practice, offering insights distinct from those obtained through
- [Advancing Knowledge on Drugs Linked to Pediatric SJS-TEN](https://drug-card.io/blog/advancing-knowledge-on-drugs-linked-to-pediatric-sjs-ten/) - Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare yet severe reactions affecting the skin and mucous membranes, leading to blistering and detachment of outer layers. During the acute phase, patients may endure various systemic complications, with long-term effects often profoundly disabling. While drugs are the primary triggers, followed by infectious and autoimmune factors,
- [Hidden Dangers of NSAID Use After 20 Weeks of Pregnancy](https://drug-card.io/blog/hidden-dangers-of-nsaid-use-after-20-weeks-of-pregnancy/) - People widely use non-steroidal anti-inflammatory drugs (NSAIDs) for their analgesic, antipyretic, and anti-inflammatory properties. Commonly prescribed and over-the-counter NSAIDs, such as ibuprofen, naproxen, and diclofenac, offer significant benefits for pain management and inflammation control. However, their use during pregnancy, particularly beyond the 20th week, has raised considerable safety concerns. Pharmacovigilance specialists must be vigilant in
- [Tackling Medication Errors with Pharmacovigilance](https://drug-card.io/blog/tackling-medication-errors-with-pharmacovigilance/) - Medication errors pose a significant challenge within global healthcare systems. These errors, which can occur at any stage of the medication process, from prescription to administration, have serious implications for patients. Imagine administering medication to the wrong patient, prescribing the incorrect dosage, overlooking necessary medications, or mistakenly entering orders. This article explores the types of
- [The Economic Edge of Automated Medical Literature Monitoring in Pharmacovigilance](https://drug-card.io/blog/the-economic-edge-of-automated-medical-literature-monitoring-in-pharmacovigilance/) - In modern pharmacovigilance, monitoring medical literature plays a crucial role in timely detecting information regarding drug safety. Recently, an increasing number of companies have adopted automated solutions for literature monitoring, significantly impacting their economic operations. Cost Reduction in Monitoring Automating the process of monitoring medical literature significantly reduces costs compared to manual methods. The primary
- [Male Fertility Endangered by Common Medications](https://drug-card.io/blog/male-fertility-endangered-by-common-medications/) - In recent years, the spotlight has turned towards an often-overlooked aspect of men's health: the effects of medications on male fertility. While the benefits of these medications are widely recognized, the potential consequences for male reproductive health warrant careful consideration. This article delves into how various pharmaceutical drugs can affect male fertility and the mechanisms
- [Оновлення DrugCard: Покращення процесів та звітності](https://drug-card.io/blog/onovlennia-drugcard-pokrashchennia-protsesiv-ta-zvitnosti/) - Раді повідомити про майбутні покращення функціоналу активностей та звітності на нашій платформі. Ці зміни розроблені для оптимізації процесів та покращення вашого досвіду як користувача. Нижче наводимо детальне порівняння існуючих функцій та майбутніх змін. Запланований термін впровадження – до кінця червня. Ми повідомимо вас про точну дату, коли ці зміни набудуть чинності. Зміни функціоналу Зміни в
- [DrugCard Update Notification: Workflow and Reporting Enhancements](https://drug-card.io/blog/drugcard-update-notification-workflow-and-reporting-enhancements/) - We are pleased to announce upcoming enhancements to our platform's workflow and reporting functionalities. These changes are designed to streamline processes and improve your user experience. Below is a detailed comparison of the existing features versus the upcoming changes. The planned timeline for implementation is until the end of June. We will notify you of
- [A Closer Look at a Cardiac Drug's Ocular Side Effects](https://drug-card.io/blog/a-closer-look-at-a-cardiac-drug-s-ocular-side-effects/) - Doctors widely use amiodarone, a potent antiarrhythmic medication, to manage and treat various cardiac arrhythmias, including atrial fibrillation and ventricular tachycardia. While its efficacy in stabilizing heart rhythms is well-documented, amiodarone's impact on the eyes is a topic of significant clinical interest. This article explores the intricate relationship between amiodarone and eye disorders, highlighting the
- [Contrasting FDA and EMA Regulatory Decision-Making in Pharmacovigilance](https://drug-card.io/blog/contrasting-fda-and-ema-regulatory-decision-making-in-pharmacovigilance/) - Monitoring the effects of medicinal products post-licensure is pivotal for upholding drug safety through pharmacovigilance. This essential practice involves deciding whether a drug should remain on the market, be withdrawn, or continue with specific usage restrictions - a process central to regulatory decision-making worldwide. The U.S. Food and Drug Administration (FDA) and the European Medicines
- [Azithromycin Misuse in COVID-19 and Echoes in Medical Literature](https://drug-card.io/blog/azithromycin-misuse-in-covid-19-and-echoes-in-medical-literature/) - As the COVID-19 pandemic unfolded, the global medical community faced unprecedented challenges. In the early stages, clinicians explored various therapeutic options to combat the virus, often repurposing existing medications. One such drug was azithromycin, a widely used antibiotic known for its broad-spectrum antimicrobial activity. However, its use in COVID-19 treatment has raised significant concerns about
- [High-Alert Medications and the Role of Pharmacovigilance](https://drug-card.io/blog/high-alert-medications-and-the-role-of-pharmacovigilance/) - High-alert medications (HAMs) are paradoxical in healthcare: they are indispensable for treatment, yet they pose significant risks if not handled with precision. While mistakes with these medications don't necessarily happen more often, the consequences can be dire. Understanding and mitigating these risks is crucial to pharmacovigilance, ensuring patient safety and optimizing therapeutic outcomes. What Are
- [Semaglutide and Food Issues](https://drug-card.io/blog/semaglutide-and-food-issues/) - According to the WHO, in 2022, 2.5 billion adults aged 18 and older were overweight, including over 890 million adults living with obesity. This means that 43% of adults were overweight, a significant increase from 1990 when the figure was 25%. Given these statistics, it's no surprise that a new class of weight loss drugs
- [Delayed Adverse Drug Reactions: Unmasking Hidden Perils](https://drug-card.io/blog/delayed-adverse-drug-reactions-unmasking-hidden-perils/) - In the world of pharmaceuticals, adverse drug reactions (ADRs) are a well-known and heavily monitored risk. However, healthcare providers often anticipate and manage immediate ADRs, but delayed adverse drug reactions (DADRs) can silently emerge years after starting therapy. These reactions are particularly insidious because clinicians can easily overlook or misattribute them to other causes, complicating
- [Malignant Hyperthermia: Rising Cases in Medical Literature](https://drug-card.io/blog/malignant-hyperthermia-rising-cases-in-medical-literature/) - Malignant hyperthermia is a rare but life-threatening disorder triggered by specific anesthetic agents. It causes a rapid rise in body temperature and severe muscle contractions, which can lead to serious complications or death if not treated promptly. Although it can affect any patient during the perioperative period, children are particularly vulnerable, with a five-fold higher
- [PubMed and DrugCard: Streamlining Pharmacovigilance](https://drug-card.io/blog/pubmed-and-drugcard-streamlining-pharmacovigilance/) - Pharmacovigilance (PV) is vital for maintaining the safety and effectiveness of medicinal products. A key aspect of PV is literature monitoring, where specialists regularly review scientific publications to detect potential adverse drug reactions (ADRs), emerging safety issues, and new insights into drug use. Among the tools used for this purpose, PubMed is a go-to resource
- [Drug-Induced Nightmares: When Dreams Turn Dark](https://drug-card.io/blog/drug-induced-nightmares-when-dreams-turn-dark/) - Nightmares, those haunting visions that disturb our sleep, are a shared experience. But when they are induced by medication, they can become more than just unsettling - they can signal serious underlying issues. For the pharmacovigilance community, understanding and addressing drug-induced nightmares is crucial in ensuring patient safety and well-being. We'll delve into this topic
- [Referral Procedures: How the EU Safeguards Medicines](https://drug-card.io/blog/referral-procedures-how-the-eu-safeguards-medicines/) - Ensuring the safety and efficacy of medicines is paramount in the European Union. One key mechanism that regulatory authorities use to manage and harmonize decisions on human medicines is the referral procedure. Referral procedures are critical in the European Medicines Agency's (EMA) framework. They address safety concerns, efficacy issues, and the need for consistent regulation
- [Foreign Body Reactions and Their Impact on Pharmacovigilance](https://drug-card.io/blog/foreign-body-reactions-and-their-impact-on-pharmacovigilance/) - Foreign body reaction (FBR) is a significant concern in pharmacovigilance, particularly in medical devices, implantable drug delivery systems, and injectable medications. This complex immune response can have serious implications for patient safety and the overall effectiveness of therapeutic interventions. For pharmacovigilance specialists, understanding FBR is crucial for monitoring, reporting, and managing adverse events related to
- [Social Media Drug Safety Dilemma](https://drug-card.io/blog/social-media-drug-safety-dilemma/) - In the last decade, the proliferation of social media platforms has transformed how information is shared, discussed, and consumed globally. The latest data shows that 5.17 billion people use social media as of 2024, equivalent to 63.7% of the world's population. Besides, an average user spends 2 hours and 20 minutes daily on social media
- [World Patient Safety Day: Safety is About Partnership](https://drug-card.io/blog/world-patient-safety-day-safety-is-about-partnership/) - Patient safety is the foundation of quality healthcare, ensuring individuals receive the correct treatment in a safe environment. In today's healthcare landscape, safety is more than just a protocol - it's a shared responsibility between patients, healthcare providers, and pharmacovigilance professionals. World Patient Safety Day, celebrated annually on September 17th, emphasizes this collective effort and
- [Minoxidil Mayhem: When Hair Restoration Goes Wrong](https://drug-card.io/blog/minoxidil-mayhem-when-hair-restoration-goes-wrong/) - Hair loss, or alopecia, is a prevalent concern impacting millions globally. According to the National Alopecia Areata Foundation, approximately 2% of people worldwide will experience hair loss due to alopecia areata in their lifetime. When taking this statistic into account, approximately 160 million people globally have had, currently have, or will have alopecia areata. For
- [Dietary Supplements and Risks Lurking in Everyday Use](https://drug-card.io/blog/dietary-supplements-and-risks-lurking-in-everyday-use/) - Pharmacovigilance specialists don't just track adverse reactions from prescription drugs - they often stumble upon unexpected cases involving everyday substances like dietary supplements. Leveraging the DrugCard platform, we've unearthed some truly intriguing cases. Today, let's delve into two standouts: one revolving around caffeine, the world's favorite stimulant, and the other tied to a trending weight-loss
- [Dispensing Errors and How to Prevent Medication Safety Risks](https://drug-card.io/blog/dispensing-errors-and-how-to-prevent-medication-safety-risks/) - Medication safety is essential to achieving optimal health outcomes. As the volume of prescriptions continues to rise worldwide, understanding the types of dispensing errors that can occur - and how to prevent them - has become increasingly vital. Dispensing errors threaten patient safety, leading to unwanted and potentially severe adverse events. In many cases, these
- [Pseudoephedrine at a Crossroad: Relief or Risk?](https://drug-card.io/blog/pseudoephedrine-at-a-crossroad-relief-or-risk/) - Pseudoephedrine, widely known for its use in over-the-counter (OTC) decongestants, has been a staple in cold and flu treatments for decades. Its effectiveness in alleviating nasal congestion has made it a go-to option for millions. However, recent safety concerns have cast a spotlight on this common drug, particularly regarding its association with serious conditions such
- [Hiccups as the Unlikely Adverse Drug Reaction That Won't Quit](https://drug-card.io/blog/hiccups-as-the-unlikely-adverse-drug-reaction-that-won-t-quit/) - In the vast pharmacovigilance world, serious adverse reactions often take the spotlight. These include life-threatening conditions, severe allergic reactions, and irreversible organ damage. But amid adverse drug reaction (ADR), a reaction exists that is more of a nuisance than a threat. However, it can be equally persistent and disruptive: hiccups. Hiccups are a not uncommon
- [Polypharmacy and the Complex Maze of Drug Interactions in Pharmacovigilance](https://drug-card.io/blog/polypharmacy-and-the-complex-maze-of-drug-interactions-in-pharmacovigilance/) - In an era when patients, especially the elderly, are often prescribed multiple medications, polypharmacy has become a significant issue in healthcare. While these prescriptions aim to manage various coexisting conditions, they also present complex challenges. Polypharmacy is not just about multiple medications but the potential cocktail of interactions that can lead to adverse drug reactions
- [MedSafetyWeek Unites the World for Safer Medicines](https://drug-card.io/blog/medsafetyweek-unites-the-world-for-safer-medicines/) - In today's interconnected world, the safety of medications is a shared responsibility. Each year, MedSafetyWeek brings together healthcare professionals, patients, and regulators from around the globe to spotlight the crucial role of reporting adverse drug reactions (ADRs). As pharmacovigilance specialists, you know that timely ADR reporting can be the difference between life and death for
- [Cross-Resistance in Focus: How Anticonvulsants Affect Muscle Relaxant Efficacy](https://drug-card.io/blog/cross-resistance-in-focus-how-anticonvulsants-affect-muscle-relaxant-efficacy/) - Imagine a patient on long-term anticonvulsant therapy who unexpectedly requires surgery. As the anesthesiologist administers a non-depolarizing muscle relaxant (NDMR), they may be surprised by the medication's reduced effectiveness. The culprit? Cross-resistance is a fascinating pharmacological phenomenon in which anticonvulsant drugs alter the efficacy of NDMRs. The Chemistry of Cross-Resistance Cross-resistance occurs when exposure to
- [Long QT Syndrome: A Silent Risk in Pharmacovigilance](https://drug-card.io/blog/long-qt-syndrome-a-silent-risk-in-pharmacovigilance/) - Long QT Syndrome (LQTS) is a silent yet potentially fatal condition. It can transform a harmless heartbeat into a life-threatening arrhythmia. While some cases of LQTS have genetic origins, drug-induced LQTS remains a significant concern in pharmacovigilance. Medications like antibiotics, antifungals, and antidepressants can prolong the QT interval on an ECG, increasing the risk of
- [The Jarisch-Herxheimer Reaction or When Treatment Turns into a Crisis](https://drug-card.io/blog/the-jarisch-herxheimer-reaction-or-when-treatment-turns-into-a-crisis/) - Imagine you're treating an infection, and instead of feeling better, your patient feels worse - much worse. Fever, chills, headaches, and an alarming flare-up of their symptoms send panic through the room. Is it an allergic reaction? Did you pick the wrong drug? No, it's probably the Jarisch-Herxheimer Reaction (JHR) - a rare and paradoxical
- [Cardiac Toxicity that Redefined Pharmacovigilance](https://drug-card.io/blog/cardiac-toxicity-that-redefined-pharmacovigilance/) - In the 1980s, two groundbreaking drugs, Seldane (Terfenadine) and Hismanal (Astemizole), revolutionized allergy treatment by becoming the first non-sedating antihistamines. They provided effective relief without the drowsiness commonly associated with older antihistamines, transforming perceptions of antihistamine safety.However, the very characteristic that made these drugs appealing - the absence of sedation - also led to unforeseen
- [Off-Label Marketing vs. Off-Label Use: A Thin Line in Pharmacovigilance](https://drug-card.io/blog/off-label-marketing-vs-off-label-use-a-thin-line-in-pharmacovigilance/) - There’s a fine line between innovation and violation regarding drug safety and regulation. Off-label use - prescribing drugs for conditions not officially approved - has been a cornerstone of medical practice, driving new therapeutic insights. But when off-label marketing enters the picture, the story shifts from patient-centric care to corporate overreach, often at the expense
- [Administration Errors or When Good Drugs Go Wrong](https://drug-card.io/blog/administration-errors-or-when-good-drugs-go-wrong/) - Pharmacovigilance often focuses on drugs' inherent risks - side effects, interactions, and long-term consequences. But what happens when healthcare providers give the drug to the right patient in the wrong place? Administration errors - mistakes that occur during prescribing, dispensing, or giving medications - are one of the most preventable causes of patient harm. Yet,
- [Vanessa's Law and the Fight for Safer Medications](https://drug-card.io/blog/vanessa-s-law-and-the-fight-for-safer-medications/) - The tragic story of Vanessa Young stands as a poignant reminder of the human cost of preventable medical errors. In 2000, 15-year-old Vanessa died of a cardiac arrhythmia caused by cisapride, a prescription drug that was later withdrawn from the market. Her death and her father's tireless advocacy led to the passage of Vanessa's Law
- [Antibiomania: How Antibiotics Can Affect the Mind](https://drug-card.io/blog/antibiomania-how-antibiotics-can-affect-the-mind/) - Antibiotics are often hailed as one of the most outstanding achievements in modern medicine. They have revolutionized healthcare by effectively treating infections and saving millions of lives. From treating bacterial infections to preventing the spread of disease, antibiotics have played a pivotal role in improving public health worldwide. However, alongside their numerous benefits, antibiotics come
- [Metamizole and the Price of Pain Relief](https://drug-card.io/blog/metamizole-and-the-price-of-pain-relief/) - Pain relief is essential in healthcare, but what happens when the remedy itself becomes the problem? Metamizole, a widely used non-opioid analgesic, sparks a long-standing debate due to its powerful pain-relieving and fever-reducing properties, yet severe, sometimes fatal side effects plague it. The primary concern is the drug’s association with agranulocytosis, a life-threatening condition where
- [Probiotics Can Be Risky Too](https://drug-card.io/blog/probiotics-can-be-risky-too/) - Probiotics are often praised for their health benefits, but what happens when beneficial bacteria become harmful? The DrugCard platform recently identified an intriguing case in the medical literature that shows even “good bacteria” can pose risks, particularly in vulnerable individuals. Lactobacillus species are well-known for their probiotic properties and are commonly found in live culture
- [Risk Minimisation Measures and Their Ripple Effect](https://drug-card.io/blog/risk-minimisation-measures-and-their-ripple-effect/) - In the intricate pharmacovigilance world, additional risk minimisation measures (aRMMs) serve as critical safeguards against adverse drug reactions (ADRs). These measures, designed to enhance patient safety, range from regulatory restrictions to educational programs and Direct Healthcare Professional Communications (DHPCs). While their primary goal is to mitigate risks, an intriguing phenomenon emerges - DHPCs and other
- [Drug-Induced Oral Reactions – A Bitter Truth](https://drug-card.io/blog/drug-induced-oral-reactions-a-bitter-truth/) - Our perception of reality relies entirely on our five senses - hearing, sight, smell, taste, and touch - first identified by Aristotle. When one or more of these senses is impaired, it can cause significant discomfort. If this impairment results from an adverse drug reaction, the concern becomes even more critical. In this article, we
- [Drug-Drug Interactions Risk Patient Safety](https://drug-card.io/blog/drug-drug-interactions-risk-patient-safety/) - Drug-drug interactions (DDIs) can silently turn essential medications into serious health risks. While some interactions are well-documented, others remain unnoticed until they cause harm. The DrugCard platform has identified several alarming cases in medical literature, highlighting the importance of recognizing and managing these interactions. Here are three real-life cases that emphasize why vigilance in pharmacovigilance
- [Dechallenge and Rechallenge for Proving Drug Causality](https://drug-card.io/blog/dechallenge-and-rechallenge-for-proving-drug-causality/) - Pharmacovigilance resembles detective work, where specialists examine clues hidden in patient reports, medical records, and clinical outcomes. Among the many investigative tools available, dechallenge and rechallenge tests serve as some of the most compelling methods for confirming whether a drug is responsible for an adverse reaction. These techniques help pharmacovigilance specialists move from suspicion to
- [Amoxicillin Rash or The Symptom That Confuses Doctors](https://drug-card.io/blog/amoxicillin-rash-or-the-symptom-that-confuses-doctors/) - A seven-year-old girl arrives at the hospital with a fever, red eyes, swollen lymph nodes, lip redness, and a mysterious rash. At first, doctors suspect a drug reaction. But as the case unfolds, it becomes clear that the diagnosis isn't so simple. Could it be Kawasaki disease, a viral rash, or something else entirely? This
- [GLP-1 Agonists Powerful Results, But What’s the Catch](https://drug-card.io/blog/glp-1-agonists-powerful-results-but-what-s-the-catch/) - Glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide and tirzepatide, have transformed the treatment of type 2 diabetes and obesity. However, as their use grows, so do safety concerns. Recent studies have linked semaglutide to a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION). The DrugCard platform has also identified a new study investigating
- [Accidental Drug Ingestion in Children: A Pharmacovigilance Wake-Up Call](https://drug-card.io/blog/accidental-drug-ingestion-in-children-a-pharmacovigilance-wake-up-call/) - Accidental drug ingestion occurs when a child unintentionally consumes a medication, leading to potential toxicity. Young children, particularly those under five years old, are at the highest risk due to their natural curiosity and tendency to explore their environment by putting objects in their mouths. For example, in 2022, 76.4% of all calls to U.S.
- [Metformin Side Effect That Needs to Stay on Your Radar](https://drug-card.io/blog/metformin-side-effect-that-needs-to-stay-on-your-radar/) - Metformin is a common medication used to treat type 2 diabetes. It's well-known for its ability to lower blood sugar levels effectively. However, many people who take metformin long-term may not realize it can lead to a deficiency in vitamin B12. Moreover, a recent case report uncovered by the DrugCard platform highlights the real-world consequences
- [Smoking Shifts Lungs and Medication Outcomes](https://drug-card.io/blog/smoking-shifts-lungs-and-medication-outcomes/) - Cigarette smoking and drug effects are an underexplored but crucial topic in pharmacovigilance. While most discussions around drug interactions focus on food, alcohol, or other medications, cigarette smoke is often overlooked. However, smoking can significantly alter the pharmacokinetics and pharmacodynamics of many drugs, leading to reduced efficacy, unexpected adverse drug reactions (ADRs), or toxicity. In
- [COVID-19 Vaccine Still Raising Questions](https://drug-card.io/blog/covid-19-vaccine-still-raising-questions/) - The COVID-19 pandemic may be officially over. The World Health Organization (WHO) has declared that it is no longer a global health emergency. But for scientists and healthcare professionals, the story continues, especially when it comes to adverse COVID-19 vaccine reactions. Even today, medical journals continue to publish new reports. These reports highlight rare, delayed,
- [Pharmacovigilance in Older Adults is a Lifeline for Safer Aging](https://drug-card.io/blog/pharmacovigilance-in-older-adults-is-a-lifeline-for-safer-aging/) - People today are living longer, with most reaching their sixties and beyond. Every country is seeing a rise in the number and proportion of older adults. According to WHO, by 2030, 1 in 6 people worldwide will be 60 or older. By 2050, that number will double to 2.1 billion, and those aged 80 or
- [Unexpected Adverse Event or Future Treatment?](https://drug-card.io/blog/unexpected-adverse-event-or-future-treatment/) - Unknown drug side effects often pose a risk to patient safety. However, in rare cases, an unexpected adverse event can open the door to a new therapeutic indication. Understanding when this shift happens - and how pharmacovigilance specialists can support it - is essential. This article explores a recent literature review uncovered by the DrugCard
- [Drug Class Effect: Why EMA is Raising a Red Flag](https://drug-card.io/blog/drug-class-effect-why-ema-is-raising-a-red-flag/) - On May 8, 2025, the European Medicines Agency (EMA) made an announcement that got many in the drug safety field talking. They decided to update the product information for medicines containing finasteride and dutasteride, warning about the risk of suicidal thoughts and behaviours. But here's where it gets interesting: there's no clear proof that one
- [Fentanyl Patch Aspiration That Fooled Everyone Until the End](https://drug-card.io/blog/fentanyl-patch-aspiration-that-fooled-everyone-until-the-end/) - What happens when a transdermal pain patch goes off course, straight into the lungs? During routine medical literature monitoring, the DrugCard platform uncovered a rare and striking case of fentanyl patch aspiration. This incident challenges our usual understanding of adverse drug reactions. It wasn't the drug's dose, chemical structure, or an interaction that caused harm
- [Updated Drug Indications Aim to Curb Antimicrobial Resistance](https://drug-card.io/blog/updated-drug-indications-aim-to-curb-antimicrobial-resistance/) - The European Medicines Agency (EMA) recently announced significant changes involving updated drug indications for one of the most commonly used antibiotics: azithromycin. The Committee for Medicinal Products for Human Use (CHMP) decided to revise, harmonise, and remove several previously approved indications across the EU. As a result, this decision targets one of the most pressing
- [Non-Drug Reactions That Surprise Medical Experts](https://drug-card.io/blog/non-drug-reactions-that-surprise-medical-experts/) - Medical literature is full of fascinating stories about adverse drug reactions. The DrugCard platform discovers new cases daily, shedding light on how drugs can sometimes cause unexpected problems. But not all medical surprises come from drugs. Occasionally, unusual non-drug reactions emerge, revealing intriguing medical mysteries caused by foods, environmental toxins, or social media trends. In
- [Medicine Shortages: When the Pharmacy Shelf Is Empty](https://drug-card.io/blog/medicine-shortages-when-the-pharmacy-shelf-is-empty/) - Medicine shortages may seem like a logistical or supply chain issue. Something for procurement teams, regulators, or distributors to worry about. But step closer, and you'll see that the roots of many shortages are entwined with pharmacovigilance. Yes, drug safety and supply disruptions often share the same origin story. Let's unravel how. Safety Concerns and
- [5 Smart Ways to Streamline Handling Adverse Drug Reaction Reports](https://drug-card.io/blog/5-smart-ways-to-streamline-handling-adverse-drug-reaction-reports/) - Handling adverse drug reaction reports is a critical responsibility in pharmacovigilance. However, with rising volumes of safety data from various sources - patients, healthcare professionals, and scientific journals - the manual process can become overwhelming. Fortunately, technology now offers powerful ways to streamline and improve adverse reaction handling. This article explores five smart strategies to
- [Top 5 Core Pharmacovigilance Documents You Shouldn't Forget](https://drug-card.io/blog/top-5-core-pharmacovigilance-documents-you-shouldn-t-forget/) - In pharmacovigilance, documentation isn't just a regulatory formality - it's the backbone of compliance, transparency, and patient safety. Certain documents are essential, whether prepping for an inspection, onboarding a new product, or managing signal detection workflows. So, what are the must-haves in your PV toolkit? Let's dive into the Top 5 pharmacovigilance documents you should
- [Homeopathic Medicines and a Risk No One Saw Coming](https://drug-card.io/blog/homeopathic-medicines-and-a-risk-no-one-saw-coming/) - Homeopathic medicines are often considered safe due to their extreme dilutions. Many patients and healthcare professionals assume these remedies carry little risk. However, rare adverse drug reactions (ADRs) can still occur - and when they do, the consequences may be serious. A recently discovered case in the medical literature, identified through the DrugCard platform, reveals
- [Foreign Language Syndrome or When ADRs Speak Another Language](https://drug-card.io/blog/foreign-language-syndrome-or-when-adrs-speak-another-language/) - The DrugCard platform is known for its ability to detect adverse drug reactions (ADRs) in multilingual literature. One powerful feature is its instant English translation - you can analyse Romanian, Serbian, or any other language article in seconds. But what happens when the adverse reaction itself speaks a different language? This is not science fiction.
- [Addendum to the Clinical Overview Supporting Safety Decisions](https://drug-card.io/blog/addendum-to-the-clinical-overview-supporting-safety-decisions/) - When pharmacovigilance specialists consider regulatory submissions, they usually focus on the PSUR, RMP, or DSUR. But one document quietly plays a pivotal role in benefit-risk evaluation during variation procedures and referral assessments: the Addendum to the Clinical Overview (ACO). At first glance, the ACO is just another document. But dig deeper, and it’s a powerful
- [Nocebo Effect or When the Mind Becomes the Side Effect](https://drug-card.io/blog/nocebo-effect-or-when-the-mind-becomes-the-side-effect/) - What if a patient's symptoms aren't caused by a drug's chemical properties, but by their expectations? Welcome to the world of the nocebo effect - a phenomenon where negative expectations lead to adverse symptoms, even in the absence of pharmacological action. While often overshadowed by placebo discussions, the nocebo effect has profound implications for pharmacovigilance,
- [Precautionary Measures in PV Show How Safety Comes First](https://drug-card.io/blog/precautionary-measures-in-pv-show-how-safety-comes-first/) - Precautionary measures are at the heart of pharmacovigilance, where proactive safety actions can mean the difference between protection and peril. Regulatory agencies are not just passive observers - they actively monitor, assess, and intervene when necessary to safeguard public health. For example, what happens when a vaccine designed to protect the vulnerable becomes a potential
- [Drug Discontinuation Needs More Attention in Drug Safety Monitoring](https://drug-card.io/blog/drug-discontinuation-needs-more-attention-in-drug-safety-monitoring/) - In pharmacovigilance, we often focus on what happens after a drug is taken - rash, liver damage, arrhythmia. But what about what happens when a drug is not taken? Or worse - intentionally stopped? One of the most overlooked dangers in drug safety is drug discontinuation. Whether it's due to side effects, lack of awareness,
- [Drug Infusion Rate and How Speed Affects ADRs](https://drug-card.io/blog/drug-infusion-rate-and-how-speed-affects-adrs/) - When we think about drug safety, we usually focus on the medicine itself - its dose, formulation, and potential interactions. But another critical factor often hides in plain sight: the drug infusion rate. In pharmacovigilance, timing matters. How quickly a drug enters the bloodstream can be the difference between a smooth recovery and a dangerous
- [Masking of Personal Data in Pharmacovigilance](https://drug-card.io/blog/masking-of-personal-data-in-pharmacovigilance/) - In pharmacovigilance, patient safety always comes first. However, as regulators and industry professionals know, protecting personal data is equally vital. The upcoming GVP Module VI Addendum II - Masking of personal data in individual case safety reports (ICSRs), effective 25 July 2025, marks a significant shift in how companies handle sensitive information. This article breaks
- [Contact Lens Safety from a Pharmacovigilance Perspective](https://drug-card.io/blog/contact-lens-safety-from-a-pharmacovigilance-perspective/) - Pharmacovigilance typically focuses on monitoring the safety of medicines, vaccines, and biologics. Yet, the scope of patient safety surveillance extends further - to medical devices and health-related products. Among these, contact lens hold a unique position. They are widely used and directly interface with one of the body’s most sensitive structures - the cornea. Worldwide,
- [“Ozempic Face” It’s More Than Just a Cosmetic Concern](https://drug-card.io/blog/ozempic-face-it-s-more-than-just-a-cosmetic-concern/) - Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is widely prescribed for type 2 diabetes and has gained immense popularity as a weight loss treatment. Celebrity endorsements and social media buzz have fueled unprecedented demand. Dramatic before-and-after pictures have drawn further attention to semaglutide as a weight loss tool. While effective in lowering blood sugar and
- [Pharmacovigilance Terminology Key Definitions for Beginners](https://drug-card.io/blog/pharmacovigilance-terminology-key-definitions-for-beginners/) - Pharmacovigilance is a global discipline. Professionals worldwide share safety data daily. But without a common language, misunderstandings can arise. That is why terminology is not just jargon - it is the foundation of effective drug safety. Are you planning to start a career in pharmacovigilance? Or have you just joined a PV team and feel
- [DrugCard’s Pharmacovigilance Team Success](https://drug-card.io/blog/drugcard-s-pharmacovigilance-team-success/) - It is often easy to speak about the achievements of our clients, but we sometimes underestimate our own successes - pushing them into the shadows, thinking that the milestones our teams reach don’t matter as much. However, after numerous conversations with industry peers and demo calls with potential clients, we realized something important: the numbers
- [Specific Adverse Reaction Follow-up Questionnaires in Pharmacovigilance](https://drug-card.io/blog/specific-adverse-reaction-follow-up-questionnaires-in-pharmacovigilance/) - Specific Adverse Reaction Follow-up Questionnaires (Specific AR FUQs) are one of the most powerful - yet often overlooked - tools in pharmacovigilance. Every safety story begins with an Individual Case Safety Report (ICSR), but these reports are rarely complete. A missing lab value, an unclear timeline, or the absence of medical history can turn a
- [Paracetamol and Pregnancy Safety Debate among Regulators](https://drug-card.io/blog/paracetamol-and-pregnancy-safety-debate-among-regulators/) - Paracetamol, known as acetaminophen, is one of the most widely used painkillers and fever reducers worldwide. While the US and Japan use the name acetaminophen, Europe and most of the world call it paracetamol. However, paracetamol and pregnancy remain at the center of a new global discussion. While the drug is widely used as a
- [How AI in Pharmacovigilance Supports Experts Without Replacing Them](https://drug-card.io/blog/how-ai-in-pharmacovigilance-supports-experts-without-replacing-them/) - Today, pharmacovigilance teams face an overwhelming influx of information. New clinical trials, scientific publications, healthcare provider and patient reports, digital channels, and social media generate continuous data streams. Traditional manual workflows cannot keep pace. Specialists cannot realistically review hundreds or thousands of new reports daily and identify which require immediate attention. This is where Artificial
- [Orphan Drugs and What Makes Their Pharmacovigilance Unique](https://drug-card.io/blog/orphan-drugs-and-what-makes-their-pharmacovigilance-unique/) - The world of orphan drugs is both fascinating and challenging. These medicines are developed to treat rare diseases - conditions that affect only a small fraction of the population. Yet their rarity is precisely what makes their safety monitoring so complex. Only a few patients have ever used orphan drugs before they reach the market.
- [What You Should Know Before Starting a Career in Pharmacovigilance](https://drug-card.io/blog/what-you-should-know-before-starting-a-career-in-pharmacovigilance/) - Are you thinking about starting a career in pharmacovigilance? This growing field is crucial in protecting patients and ensuring that medicines remain safe throughout their lifecycle. Pharmacovigilance is more than data entry or case collection - it's about understanding risks, identifying patterns, and helping save lives. Let's explore what you should know before beginning your
- [MedSafetyWeek 2025: Together We Can Make Medicines Safer](https://drug-card.io/blog/medsafetyweek-2025-together-we-can-make-medicines-safer/) - Every November, the global pharmacovigilance community comes together under a shared purpose - to make medicines safer for everyone. This happens through #MedSafetyWeek, an international social media campaign led by the Uppsala Monitoring Centre (UMC). In 2025, the campaign will celebrate its tenth anniversary, running from November 3 to 9. This year’s theme - “We can
- [7 Things Only Pharmacovigilance Specialist Truly Understand](https://drug-card.io/blog/7-things-only-pharmacovigilance-specialist-truly-understand/) - Pharmacovigilance specialists live in a fascinating world where medicine, science, and detective work intersect. They spend their days (and often nights) reviewing safety data, investigating reports, and trying to make sense of complex clinical realities - all to protect patients from harm. While their work might seem invisible to the outside world, pharmacovigilance professionals know
- [Listen to the Antibiotic Alarm During World AMR Awareness Week](https://drug-card.io/blog/listen-to-the-antibiotic-alarm-during-world-amr-awareness-week/) - Antimicrobial resistance (AMR) is one of the most urgent global health threats of our time. AMR occurs when microorganisms evolve to withstand antimicrobial treatments that previously killed them or inhibited their growth. Among these medicines, antibiotics are the most widely used - and the most endangered. Every year from 18 to 24 November, the world
- [Pharmacovigilance Made Smarter with New AI Literature Screening on the Platform](https://drug-card.io/blog/pharmacovigilance-made-smarter-with-new-ai-literature-screening-on-the-platform/) - A few years ago, a pharmacovigilance specialist’s morning always looked the same. Dozens of tabs open, endless searches through databases, manually compiled lists of journals, and hundreds of articles to review. Every new publication required time, patience, and a focused approach. In that routine, it was easy to miss something important - simply because human
- [5 Things to Say NO in Literature Monitoring](https://drug-card.io/blog/5-things-to-say-no-in-literature-monitoring/) - How many times have you caught yourself reading articles that, in the end, added little to no value to your work? You open PDF after PDF, carefully read abstracts, and then realise: this material doesn’t actually help assess drug safety. Literature monitoring in pharmacovigilance isn’t just about finding new signals - it’s also about filtering
- [How to Explain Your Job in PV Without Losing People in 30 Seconds](https://drug-card.io/blog/how-to-explain-your-job-in-pv-without-losing-people-in-30-seconds/) - Have you ever told someone that you work in pharmacovigilance and literally watched them mentally “leave the chat” before you even finished the sentence? You pronounce it slowly and clearly, with confidence. They nod and smile, but their eyes go blank. At that moment, you already know what comes next - either an awkward pause or the
- [10 Pharmacovigilance Information Sources Every PV Professional Should Read](https://drug-card.io/blog/10-pharmacovigilance-information-sources-every-pv-professional-should-read/) - Pharmacovigilance information significantly impacts the daily lives of PV professionals. You open your laptop in the morning, and before your first coffee is finished, several tabs are already open. Regulatory news. Safety alerts. Medical literature. Another case report. New risks, updated warnings, and unexpected adverse reactions continue to emerge. At DrugCard, our team lives this
- [How to Explain Your Job in PV Without Losing People in 30 Seconds (Part 2)](https://drug-card.io/blog/how-to-explain-your-job-in-pv-without-losing-people-in-30-seconds-part-2/) - In the first part, we discussed how to explain your pharmacovigilance job to colleagues or strangers in just thirty seconds. Recently, during a practical conference organised by the DrugCard team, we explored a different question while networking - how do your children and family understand what their mom or dad does at work? One colleague shared that
- [Pharmacovigilance Literature Monitoring Pre-Audit Checklist](https://drug-card.io/blog/pharmacovigilance-literature-monitoring-pre-audit-checklist/) - Adequate preparation for a pharmacovigilance audit requires careful planning and a structured approach. One of the areas most closely reviewed during inspections is the literature monitoring process. Ensuring that this process is well organised, documented, and consistently applied is critical for demonstrating compliance with regulatory requirements. How can teams ensure their processes are compliant, efficient, and
- [How DrugCard Delivered Reference SmPC Change Monitoring in Just 1.5 Months](https://drug-card.io/blog/how-drugcard-delivered-reference-smpc-change-monitoring-in-just-1-5-months/) - Speed and precision are critical requirements in regulatory and pharmacovigilance processes. Every update to a reference product’s SmPC can directly impact patient safety, regulatory compliance, and a company’s market position. Yet, despite this importance, many pharmaceutical companies still rely on manual, fragmented processes to track these changes. That is precisely where Reference SmPC change monitoring
- [Principles of Good AI Practice in Drug Development: EMA and FDA Set a Common Framework](https://drug-card.io/blog/principles-of-good-ai-practice-in-drug-development-ema-and-fda-set-a-common-framework/) - At the end of 2025, the DrugCard team hosted the first-ever practical pharmacovigilance conference in Kyiv, Ukraine, focused on applying artificial intelligence (AI) in drug safety. This landmark event highlighted that DrugCard is at the forefront of pharmacovigilance innovation, integrating AI into monitoring and safety processes. The recent announcement that EMA and FDA have established
- [Literature Monitoring for Drug Safety: Automate, Delegate, or Eliminate?](https://drug-card.io/blog/literature-monitoring-for-drug-safety-automate-delegate-or-eliminate/) - Good Pharmacovigilance Practice (GVP) places strict obligations on pharmaceutical companies to collect, assess, and act on safety data. Among these obligations, medical literature monitoring for drug safety remains one of the most resource-intensive and inspection-sensitive activities. Every new publication, case report, or regulatory update could contain signals that influence patient safety, regulatory compliance, and the
- [5 Red Flags in Pharmacovigilance Every Safety Team Must Recognise](https://drug-card.io/blog/5-red-flags-in-pharmacovigilance-every-safety-team-must-recognise/) - Looking for red flags has become almost fashionable these days - from dating apps to office politics, everyone seems to be spotting them. Pharmacovigilance is no exception. In drug safety, red flags do more than follow a trend. They warn that patient safety could be at risk. PV teams constantly monitor, analyse, and act on
- [What AI Can’t Do in Pharmacovigilance and Why It Still Matters](https://drug-card.io/blog/what-ai-can-t-do-in-pharmacovigilance-and-why-it-still-matters/) - Artificial intelligence is now embedded in pharmacovigilance workflows. It supports case intake, literature screening, duplicate detection, and even signal prioritisation. Many teams report efficiency gains and reduced manual workload. Yet despite rapid adoption, there are critical areas where AI can’t do in pharmacovigilance what human experts still must. Understanding these limitations is essential for patient
- [Decision-Making in PV: How Experts Evaluate Uncertain Safety Data](https://drug-card.io/blog/decision-making-in-pv-how-experts-evaluate-uncertain-safety-data/) - In pharmacovigilance, the most critical decisions often arise from uncertain safety data. These situations occur when information is incomplete, data conflict, and the clinical picture is far from straightforward. Real-world safety cases rarely resemble textbook examples. Patients often have comorbidities, take multiple medications simultaneously, or present with atypical disease courses or undocumented risk factors. Add
- [Core Principles of Pharmacovigilance That Will Never Change](https://drug-card.io/blog/core-principles-of-pharmacovigilance-that-will-never-change/) - Pharmacovigilance is evolving faster than ever. Artificial intelligence is transforming case intake. Automation is accelerating literature screening. Global databases are becoming more interconnected. Yet despite technological progress, these core principles of pharmacovigilance remain constant. These are not trends. They are foundations. Understanding what will never change in pharmacovigilance helps professionals stay grounded in a field that is constantly
- [Cannabis Safety in Real Life: Lessons from Literature Monitoring](https://drug-card.io/blog/cannabis-safety-in-real-life-lessons-from-literature-monitoring/) - Cannabis and its products, particularly cannabis oil containing CBD, are becoming increasingly common in modern therapeutic practice. People use them to relieve pain, anxiety, inflammation, and sleep disorders. As their use grows, questions about cannabis safety in real life are becoming increasingly important. The prevailing belief holds that CBD is “natural,” “non-psychoactive,” and “well tolerated.”
- [The Human Side of Pharmacovigilance: Stress, Workload, and Leadership in High‑Stakes Environments](https://drug-card.io/blog/the-human-side-of-pharmacovigilance-stress-workload-and-leadership-in-high-stakes-environments/) - When pharmacovigilance is discussed, the focus usually falls on processes, systems, and regulations. Case processing, signal detection, literature monitoring, periodic safety reports, inspections, and compliance requirements tend to dominate the conversation. What is often missing from this picture is the human side of pharmacovigilance. Behind every Individual Case Safety Report, every potential safety signal, and
- [Preventable Adverse Drug Reactions and the Risk of Forgotten Reactions](https://drug-card.io/blog/preventable-adverse-drug-reactions-and-the-risk-of-forgotten-reactions/) - Preventable adverse drug reactions remain a persistent and underrecognised challenge in modern healthcare. A recent case identified through DrugCard’s literature monitoring highlights a critical issue in pharmacovigilance: patients are still being re-exposed to medications that previously caused adverse drug reactions. This is not an isolated phenomenon. Evidence suggests that a significant proportion of hospital readmissions
- [Medication Safety in Women and the Burden of Contraindicated Medicines](https://drug-card.io/blog/medication-safety-in-women-and-the-burden-of-contraindicated-medicines/) - Medication safety in women of reproductive age remains one of the most complex and underrecognised challenges in modern pharmacovigilance. Researchers traditionally focus much attention on drug use during confirmed pregnancy. However, emerging evidence shows that the real risk window often begins much earlier, before clinicians detect pregnancy. Clinicians often rely on pharmacotherapy to manage chronic
- [Implementing New Systems in Pharmacovigilance Without the Pain](https://drug-card.io/blog/implementing-new-systems-in-pharmacovigilance-without-the-pain/) - Why implementing new systems in pharmacovigilance feels so risky In most industries, introducing a new tool is usually seen as a step forward. In pharmacovigilance, it often feels like a risk. This is not because teams don’t want to improve their processes. It’s because the stakes are high. Every workflow is tied to patient safety,
- [When Medicine Packaging Becomes a Lifesaver](https://drug-card.io/blog/when-medicine-packaging-becomes-a-lifesaver/) - Have you ever wondered why medicine packaging looks the way it does? Why is there so much text on medicine packaging, the colours often plain, some containers seemingly oversized, and opening them sometimes difficult? At first glance, these features may seem inconvenient or even poorly designed. In reality, they are carefully considered elements that serve
- [Nasal Decongestants and the Price of Quick Relief](https://drug-card.io/blog/nasal-decongestants-and-the-price-of-quick-relief/) - Nasal decongestants are among the most widely used medications worldwide. Available as sprays or drops, they offer fast relief from blocked noses caused by colds, flu, or allergies. Because they are sold over the counter, many people assume they are completely safe. However, recent findings from the DrugCard platform highlight that even common medicines like

## Pages

- [DrugCard - your global partner for local literature screening](https://drug-card.io/) - DrugCard - AI-powered pharmacovigilance tools & services for automated literature monitoring, regulatory intelligence and adverse events management.
- [About Us](https://drug-card.io/about-us/) - Home / About Us Meet the People Behind DrugCard Building the Future of Pharmacovigilance Discover who we are, how DrugCard began, and what drives our mission to make pharmacovigilance faster, safer, and smarter. Ask an expert Our History 2019202020212022202320242025 2019 — The idea for DrugCard was born. Brothers Artem and Dmytro Horilyk discussed ways to
- [Documents & Resources​](https://drug-card.io/documents/) - Home / Documents & Resources​ Documents & Resources All essential materials in one place: AI documentation, practical materials, and additional resources to support your work. Is Your Literature Review Missing AI Advantage This one-pager helps pharmacovigilance professionals identify inefficiencies in their manual literature monitoring and shows how AI can streamline reviews, reduce workload, and improve
- [Solution](https://drug-card.io/local-literature/) - Stay compliant and save time with automated pharmacovigilance literature monitoring. Detect safety signals early, streamline reviews, and meet global PV standards effortlessly with DrugCard
- [Services](https://drug-card.io/services/) - End-to-end drug safety and pharmacovigilance services tailored to your needs — combining expert support, smart automation, and global compliance. From literature monitoring to PV trainings
- [Adverse Event Database](https://drug-card.io/adverse-event-database/) - Simplify safety data management with our adverse event software. Enter, store, import, and export it ensuring full compliance with global drug safety standards.
- [Regulatory Intelligence](https://drug-card.io/regulatory-intelligence/) - Stay ahead of regulatory changes with DrugCard’s automated solution. Receive updates from health authorities in one place, assess impact instantly, and maintain continuous compliance.
- [Partnership](https://drug-card.io/partnership/) - Home / Partnership Partnering with you for a safer tomorrow Interested in partnering with DrugCard? Join forces with our team to help the global pharmaceutical industry automate pharmacovigilance processes. Partner with us Do you find DrugCard useful and want to make it available to your customers? Let’s partner!Whether you have an ICSR database or you’re
- [Global Literature Monitoring](https://drug-card.io/global-literature/) - AI Meets Global Databases DrugCard MLM is your AI-powered gateway to effortless global literature screening in PubMed - fast, accurate, and always up-to-date. Request a Demo Say Goodbye to Manual Searches – Let AI Handle Literature Monitoring Our platform streamlines the literature monitoring process by automating searches, categorizing relevant articles, and delivering insights from PubMed
- [Advanced AI](https://drug-card.io/advanced-ai/) - Advanced AI - Rapid Detection, Seamless Processing Detect emerging safety trends early through continuous monitoring and automated pattern recognition. Request a Demo Say Goodbye to Manual Searches – Let AI Handle Literature Monitoring Our platform scans global health authority websites in real-time, identifies relevant legislative updates, and notifies your team instantly—so you never miss a
- [Local Qualified Person for Pharmacovigilance (LQPPV)](https://drug-card.io/local-qualified-person-for-pharmacovigilance-lqppv/) - Ensure local pharmacovigilance compliance with our expert LQPPV services. We provide qualified professionals to manage safety reporting and liaise with health authorities.
- [PSUR (Periodic Safety Update Report) Services](https://drug-card.io/psur/) - Stay compliant with our PSUR services. We prepare and submit Periodic Safety Update Reports that ensure continuous drug safety evaluation and meet global regulatory requirements.
- [Signal Management](https://drug-card.io/signal-management/) - Detect, assess, and manage safety signals with precision. Our pharmacovigilance signal management services help you identify risks early and maintain full regulatory compliance.
- [ICSR Management](https://drug-card.io/icsr-management/) - Get complete ICSR management services — from case intake, medical assessment, and coding to E2B submission. Ensure regulatory compliance & PV reporting across global markets.
- [Pharmacovigilance System Master File (PSMF) Management](https://drug-card.io/pharmacovigilance-system-master-file/) - Ensure inspection readiness with our PSMF management services. We create, maintain, and update your PSMF in full compliance with EU and global PV requirements.
- [Risk Management Plan for Pharmacovigilance](https://drug-card.io/risk-management-plan-for-pharmacovigilance/) - Protect patients and meet regulatory expectations with our RMP services. We develop and maintain comprehensive Risk Management Plans to identify, assess, and minimize drug safety risks.
- [Pharmacovigilance Audit & Training Services](https://drug-card.io/pharmacovigilance-audit-amp-training-services/) - Strengthen your PV system with our expert pharmacovigilance audit and training services. Ensure compliance, improve quality, and empower your team with practical PV knowledge.
- [Pharmacovigilance Consultancy Services](https://drug-card.io/pharmacovigilance-consultancy-services/) - Optimize your drug safety operations with our pharmacovigilance consultancy services. Get expert guidance on compliance, strategy, and PV system optimization worldwide
- [eCTDlight](https://drug-card.io/drugcard-ectdlight-en/) - Submit medicinal product registrations effortlessly with DrugCard’s eCTD tool — browser-based, fully compliant with Ukraine’s 2025 eCTD standard, and license-free.
- [Simple Search by DrugCard](https://drug-card.io/simple-search/) - Free AI-powered Simple Search for pharmacovigilance teams — access local journals, view AI-generated abstracts, and find drug safety insights in seconds.
- [Contact us](https://drug-card.io/contact-us/) - Home / Contact us Want to talk? We’re here to help! Have any questions about platform features, starting a free trial, or integrating DrugCard into your pharmacovigilance system? We're here to provide all the information you need. You’ve come to the right place. Our team is here 24/7 to guide you on how to improve
- [Manual screening vs DrugCard screening](https://drug-card.io/manual-screening-vs-drugcard-screening/) - Home / Manual screening vs DrugCard screening Manual Screening vs DrugCard Screening A clearer way to compare the manual literature screening with automated PV screening Literature screening is one of those pharmacovigilance activities that looks simple from the outside, until your team has to do it every week, across multiple products, journals, countries, and languages.
- [Local Medical Journals](https://drug-card.io/local-medical-journals/) - Home / Local Medical Journals List of Local Medical Journals Explore the country-specific local medical journals already available on DrugCard. We continuously expand our database and can add any journal you need — fast and without bureaucracy. Greece - Local Medical Journals Download Spain - Local Medical Journals Download Croatia - Local Medical Journals Download
- [Заходи БПР](https://drug-card.io/zakhody-bpr/) - Home / Заходи БПР Безперервний професійний розвиток (БПР) Підтримуємо розвиток медичних фахівців через сучасні освітні заходи DrugCard виступає провайдером заходів безперервного професійного розвитку (БПР), спрямованих на актуальні виклики фармаконагляду, регуляторних вимог та застосування AI у медицині. Нормативна База Про нас DrugCard — це AI-powered платформа у сфері фармаконагляду, яка допомагає автоматизувати моніторинг літератури, регуляторні процеси
- [Why DrugCard?](https://drug-card.io/why-drugcard/) - Home / Why DrugCard? Why DrugCard? It’s time to solve your local literature screening gap Entrust your pharmacovigilance routine to us Request a Demo The local literature screening gap Common challenges for drug safety specialists Local sources managment Identifying relevant local journals Checking updates for huge number of issues Managing paid subscription and paper journals
- [Compliance](https://drug-card.io/compliance/) - Home / Compliance Compliance Infrastructure The DrugCard platform is hosted on Amazon Web Services (AWS) using an Infrastructure as a Service (IaaS) model. AWS data centers are ISO/IEC 27001 certified, ensuring a high level of information security, availability, and resilience. To ensure data protection and system availability: Daily automated backups of system data are performed;
- [Privacy Policy](https://drug-card.io/privacy-policy/) - Privacy Policy Last Updated On 29-Feb-2024 Effective Date 29-Feb-2024 This Privacy Policy describes the policies of DrugCards OÜ, Harju maakond, Tallinn, Lasnamäe linnaosa, Ruunaoja tn 3, Lasnamäe linnaosa 11415, Estonia, email: office@drug-card.io, phone: +380936166960 on the collection, use and disclosure of your information that we collect when you use our website ( https://drug-card.io/ ). (the
- [Quality Policy](https://drug-card.io/quality-policy/) - Effective Date On 15-May-2023 POLICY STATEMENT The DrugCard company develops software for medical literature screening, automating drug safety processes and provides pharmacovigilance services. Our goal is to continuously enhance our services in order to meet our clients' needs and produce high-quality values that we can take pride in. To achieve these objectives, the company intends
- [Implementation & Onboarding](https://drug-card.io/implementation-onboarding/) - Home / Implementation & Onboarding Implementation & Onboarding How We Help You Implement DrugCard We support your team at every step of implementing DrugCard - from initial introduction and setup to day-to-day use and ongoing support. This structured approach ensures compliant adoption, clear user accountability, and confident use of the platform within routine pharmacovigilance workflows.
- [News](https://drug-card.io/news/) - Home / News News & Updates Stay informed about the latest from DrugCard. Product releases, industry events, and insights from the world of pharmacovigilance. Shaping the Future of Pharmacovigilance: What We Took Away Together On June 4, 2026, over 80 pharmacovigilance professionals joined DrugCard for an online conversation with two experienced practitioners — Artem Horilyk
- [Audit Readiness](https://drug-card.io/audit-readiness/) - Home / Audit Readiness Audit Readiness with DrugCard How We Help You Stay Audit-Ready DrugCard is designed to support both MAHs and CROs in maintaining inspection-ready pharmacovigilance literature monitoring processes. “There was a request to show whether the platform found a specific article on a specific date. Thanks to the filtering, we found it and
- [Case Studies](https://drug-card.io/case-studies/) - Home / Case Studies Case studies How Our Clients Succeed with DrugCard. Real stories from companies that transformed their pharmacovigilance processes through automation and AI. SanoSwiss Case Study: One Platform for Literature Screening Across 10 Countries The story of how SanoSwiss, a healthcare company with an extensive international footprint, manages 155 products across 10 European
- [DrugCard eCTDlight](https://drug-card.io/ectdlight/) - Електронна реєстрація лікарських засобів тепер ще зручніша та відповідає вимогам 2025 року. DrugCard eCTDlight подача досьє в ДЕЦ без складних систем Оптимізуйте процес реєстрації лікарських засобів завдяки нашій платформі, яка відповідає сучасним стандартам та забезпечує швидкість і точність. ✔️Без наддорогих ліцензій ✔️Працює прямо з браузера ✔️Підтримка українською Чому eCTDlight? З 2025 року всі подачі в Україні

## My Templates

- [doc_hubspot_ai_advantage](https://drug-card.io/?elementor_library=doc_hubspot_ai_advantage) - Content Area
- [Popup_AI Advantage](https://drug-card.io/?elementor_library=popup_ai-advantage) - Content Area
- [Default Kit](https://drug-card.io/?elementor_library=default-kit-3)
- [Looking for Expert Guidance?](https://drug-card.io/?elementor_library=have-questuions) - Looking for Expert Guidance? Our team is on hand round the clock to guide you on how to enhance your literature screening or to offer consultation on your pharmacovigilance processes. Contact us
- [Author box](https://drug-card.io/?elementor_library=author-box) - Written by Panem Agency
- [Popup_LJ_Croatia](https://drug-card.io/?elementor_library=popup_lj_croatia) - Content Area
- [Другий Kyiv Drug Safety Day](https://drug-card.io/?elementor_library=kyiv-drug-safety-day-2) - Другий Kyiv Drug Safety Day Це друга практична конференція в Україні, присвячена розвитку фармаконагляду через ефективне лідерство, комунікацію та взаємодію між командами. Після фокусу на автоматизації та AI на першому заході, цього разу ми переходимо до не менш критичної теми — людського фактору у фармаконагляді.
- [Kyiv Drug Safety Day](https://drug-card.io/?elementor_library=kyiv-drug-safety-day-1) - Kyiv Drug Safety Day Це перша в Україні практична конференція, присвячена автоматизації та використанню штучного інтелекту у фармаконагляді. Ми об’єднали лідерів галузі, представників державних органів та фахівців з фармаконагляду, щоб разом:розібратися в сучасних технологіях для PV,поділитися реальними кейсами автоматизації,сформувати європейський вектор розвитку українського фармаконагляду.
- [2025](https://drug-card.io/?elementor_library=2025) - 2025 — Global scale. DrugCard now operates in 121+ countries, processes over 1 million articles, and provides AI-based global assessment, regulatory intelligence, and safety database solutions. PV services: 3 specialists, 11 projects, and 21 countries.
- [2022](https://drug-card.io/?elementor_library=2022) - 2022 — Expansion to Europe and the UK, multinational partnerships. The first European clients joined from Germany, and the team began monitoring new countries.
- [Popup_Using AI in PV](https://drug-card.io/?elementor_library=popup_using-ai-in-pv) - Content Area
- [Popup_How To Explain QPPV](https://drug-card.io/?elementor_library=popup_how-to-explain-qppv) - Content Area
- [Popup_How To Explain PV](https://drug-card.io/?elementor_library=popup_how-to-explain-pv) - Content Area
- [Popup_Pharmacovigilance services by DrugCard](https://drug-card.io/?elementor_library=popup_pharmacovigilance-services-by-drugcard) - Content Area
- [Popup_Pharmacovigilance Literature Monitoring Pre-Audit Checklist​](https://drug-card.io/?elementor_library=popup_pharmacovigilance-literature-monitoring-pre-audit-checklist) - Content Area
- [Popup_LJ_Spain](https://drug-card.io/?elementor_library=popup_lj_spain) - Content Area
- [Popup_LJ_Greece](https://drug-card.io/?elementor_library=popup_lj_greece) - Content Area
- [Popup_How to Choose the Best Software for Literature Monitoring](https://drug-card.io/?elementor_library=popup_how-to-choose-the-best-software-for-literature-monitoring) - Content Area
- [Popup_Literature](https://drug-card.io/?elementor_library=popup_literature) - Content Area
- [Popup_RegIntel](https://drug-card.io/?elementor_library=popup_regintel) - Content Area
- [Popup_Adverse_Event](https://drug-card.io/?elementor_library=popup_adverse_event) - Content Area
- [Thank you page](https://drug-card.io/?elementor_library=thank-you-page) - Content Area
- [2024](https://drug-card.io/?elementor_library=2024) - 2024 — LLM model and AI Case Intake. Our AI was first presented in Brussels at the DIA conference The company introduced an LLM model for article categorization and global literature coverage. In December, the AI Case Intake module was released, automatically extracting adverse reaction data from unstructured text. By year-end: 22 team members, 48
- [2023](https://drug-card.io/?elementor_library=2023) - 2023 — AI research and PV services. The team started training AI models on real pharmacovigilance data and launched a PV service (1 specialist, 1 project, 1 country). By year-end: 10 clients, 30 countries, 10 team members.
- [2021](https://drug-card.io/?elementor_library=2021) - 2021 — The first clients and investments. The company signed its first client in April, followed shortly by one of the largest pharmaceutical companies in the region. In December, DrugCard received its first investments from Spain and Ukraine.
- [2020](https://drug-card.io/?elementor_library=2020) - 2020 — The first version of the system was created. By August, the team completed the MVP and started reaching out to potential clients.
- [2019](https://drug-card.io/?elementor_library=2019) - 2019 — The idea for DrugCard was born. Brothers Artem and Dmytro Horilyk discussed ways to improve pharmacovigilance processes. At the time, Artem worked as a pharmacovigilance specialist, and Dmytro questioned why literature screening was still performed manually. Their friend Myroslav proposed developing code to automate the process.
- [Freelancers - [Cloned #1333]](https://drug-card.io/?elementor_library=freelancers-cloned-1333) - 2025 — Global scale. DrugCard now operates in 100+ countries, processes over 1 million articles, and provides AI-based global assessment, regulatory intelligence, and safety database solutions. PV services: 3 specialists, 11 projects, and 21 countries.
- [Freelancers](https://drug-card.io/?elementor_library=freelancers) - Free up time for other activities With DrugCard, freelancers providing literature screening and other outsourcing services can save up to 70% of their precious time and use it for other value-adding activities such as consulting, research, quality assurance, etc. Higher productivity, less work, more revenues! Talk to us
- [MAHs](https://drug-card.io/?elementor_library=mahs) - In-house local literature screening for MAHs Outsourcing of literature screening to CROs has become so widespread and common in the last 5-7 years. However, we at DrugCard strongly believe that literature screening could be done more effectively, either in-house, at both a global and local level, or with very few contractors. Managing multiple CROs across
- [CROs](https://drug-card.io/?elementor_library=cros-2) - CROs can manage more PV projects and improve screening results When pharma outsource PV processes to CROs, they expect the highest quality and maximum search results to ensure full compliance with regulatory requirements. CROs can no longer guarantee the best results if they continue to read journals from cover to cover manually. Progressive CROs continuously
- [break](https://drug-card.io/?elementor_library=break) - Home / break
- [МАХи](https://drug-card.io/?elementor_library=makhy) - Внутрішній скринінг місцевої літератури для медичних працівників Аутсорсинг скринінгу літератури для дослідницьких організацій став настільки поширеним і звичним за останні 5-7 років. Однак ми в DrugCard переконані, що скринінг літератури можна проводити більш ефективно, або власними силами, як на глобальному, так і на місцевому рівнях, або з дуже невеликою кількістю підрядників. Управління кількома CRO в
- [CROs](https://drug-card.io/?elementor_library=cros) - CRO можуть керувати більшою кількістю проектів та покращувати результати скринінгу Коли фармацевтичні компанії передають процеси PV на аутсорсинг CRO, вони очікують найвищої якості та максимальних результатів пошуку, щоб забезпечити повну відповідність нормативним вимогам. Дослідницькі організації більше не можуть гарантувати найкращі результати, якщо вони продовжують читати журнали від початку до кінця вручну. Прогресивні CRO постійно знаходять
- [Заголовок](https://drug-card.io/?elementor_library=zaholovok)
- [Header](https://drug-card.io/?elementor_library=header)
- [Default Kit](https://drug-card.io/?elementor_library=default-kit-2)
- [Default Kit](https://drug-card.io/?elementor_library=default-kit)

## news-updates

- [Shaping the Future of Pharmacovigilance: What We Took Away Together](https://drug-card.io/news-updates/shaping-the-future-of-pharmacovigilance-what-we-took-away-together/) - On June 4, 2026, over 80 pharmacovigilance professionals joined DrugCard for an online conversation with two experienced practitioners — Artem Horilyk and Julia Appelskog. We talked about careers, leadership, community, and where pharmacovigilance is heading. No checklists, no corporate messaging — just an open discussion between people who work in this field every day. The
- [Shaping the Future of Pharmacovigilance: Leadership, Communication & Community | DrugCard Webinar](https://drug-card.io/news-updates/shaping-the-future-of-pharmacovigilance-leadership-communication-community-drugcard-webinar/) - Online Webinar | June 4, 2026 | 13:00 CEST Pharmacovigilance is not just reports, deadlines, and regulatory requirements. It is people who make decisions every day that affect patient safety around the world. And it is precisely this human dimension of the work — leadership, communication, community, and the future of the profession — that
- [DrugCard Joins EUCROF as an Associate Member](https://drug-card.io/news-updates/drugcard-joins-eucrof-as-an-associate-member/) - We are excited to announce that DrugCard has officially joined the European CRO Federation (EUCROF) as an Associate Member. About EUCROF Founded to represent the Contract Research Organization sector at the European level, EUCROF brings together CROs and specialized service providers from across the continent. The federation engages directly with key regulatory bodies - including
- [DrugCard Announces Acquisition of SIA OOM to Strengthen Pharmacovigilance Presence in the Baltics](https://drug-card.io/news-updates/drugcard-announces-acquisition-of-sia-oom-to-strengthen-pharmacovigilance-presence-in-the-baltics/) - TALLINN, ESTONIA/RIGA, LATVIA – April 21, 2026 – DrugCards OÜ (brand name “DrugCard”), a leading developer of AI agents for drug safety departments, today announced the successful acquisition of 100% of the shares of SIA OOM, a specialized pharmacovigilance service provider based in Riga, Latvia. This strategic acquisition marks DrugCard’ first M&A transaction and signifies
- [The Second Kyiv Drug Safety Day: Leadership and Communication in Pharmacovigilance: The Role of Everyone](https://drug-card.io/news-updates/the-second-kyiv-drug-safety-day/) - On April 16, 2026, we held the second Kyiv Drug Safety Day conference in Kyiv — and it was a special day for our community. Over 80 participants joined us: pharmacovigilance specialists, regulatory representatives, physicians, academics, and business leaders. People who work with the drug safety system every day and understand the weight of responsibility
- [How NOT to Buy AI for Pharmacovigilance: Insights from a Talk by Our CEO, Dmytro Horilyk](https://drug-card.io/news-updates/drugcard-ceo-dmytro-horilyk-shares-key-lessons-on-ai-adoption-in-pharmacovigilance-at-edsai-2026-watch-the-talk-on-avoiding-common-ai-implementation-mistakes/) - At the European Drug Safety & AI Conference 2026, DrugCard CEO Dmytro Horilyk spoke about a challenge many pharmacovigilance teams quietly face when discussing AI adoption. The industry conversation often focuses on models, algorithms, and automation potential. Yet the biggest barrier rarely comes from technology. As Dmytro explained during the session: “AI projects don’t fail
- [DrugCard at European Drug Safety & AI 2026: Insights, Connections, and the Future of Automation](https://drug-card.io/news-updates/drugcard-at-european-drug-safety-amp-ai-2026-insights-connections-and-the-future-of-automation/) - The DrugCard team recently returned from the European Drug Safety & AI 2026 summit. This gathering served as a strategic touchpoint for our experts to engage with the latest AI trends in pharmacovigilance and to strengthen our relationships with partners and industry peers. Representing DrugCard in Barcelona were: Dmytro Horilyk, CEO Christina Kiselova, Head of

## Case-Study

- [SanoSwiss Case Study: One Platform for Literature Screening Across 10 Countries](https://drug-card.io/case-study/sanoswiss-case-study-one-platform-for-literature-screening-across-10-countries/) - The story of how SanoSwiss, a healthcare company with an extensive international footprint, manages 155 products across 10 European countries with DrugCard. Client: Location:Europe Challenge Managing the Complexities of Multi-Country Pharmacovigilance and Literature Monitoring SanoSwiss faced the challenge of managing literature monitoring across 10 countries, each with distinct languages and regulatory requirements: Processing high volumes
- [Lean Pharma Case Study: Transforming ICSR Detection with AI](https://drug-card.io/case-study/lean-pharma-case-study-transforming-icsr-detection-with-ai/) - The story of how Lean Pharma accelerated safety case detection, reduced manual review workload, and improved pharmacovigilance efficiency with DrugCard’s AI-powered literature screening and ICSR detection capabilities. Client: Location:Greece Challenge Overcoming the Limitations of Manual Literature Screening As literature volumes continued to grow, Lean Pharma faced increasing pressure to maintain efficiency and compliance: Reviewing each
- [Polpharma Case Study: Modernising Local Literature Monitoring in Pharmacovigilance](https://drug-card.io/case-study/polpharma-case-study-modernising-local-literature-monitoring-in-pharmacovigilance/) - The story of how Polpharma, one of the largest Polish pharmaceutical manufacturers operating in Ukraine for over 20 years, streamlined local pharmacovigilance literature monitoring with DrugCard. Client: Location:Ukraine Challenge Pressing Challenges in Safety Surveillance Polpharma’s pharmacovigilance workflow faced several persistent challenges: High volumes of literature require manual screening, making local market monitoring difficult to sustain.
- [OM Pharma Case Study: From Manual Review to AI-Driven PV Transformation](https://drug-card.io/case-study/om-pharma-case-study-from-manual-review-to-ai-driven-pv-transformation/) - The story of how Swiss pharmaceutical company OM Pharma transformed pharmacovigilance with AI solution DrugCard. Client: Location:Switzerland Challenge As PV activities scaled, key process limitations became evident OM Pharma faced growing pharmacovigilance demands that strained traditional manual processes: Time-consuming literature surveillance, with safety reviewers spending approximately 25 minutes per article to identify and assess relevant
- [Biofarm Case Study: Saving over 8,300 work hours with DrugCard](https://drug-card.io/case-study/biofarm-case-study-saving-over-8-300-work-hours-with-drugcard/) - The story of how Biofarm, a Poland-based pharmaceutical company with 102 products under surveillance, transformed its literature monitoring process using DrugCard’s AI-powered automation system. Client: Location:Poland, Ukraine Challenge Heavy manual workload, risk of overlooked insights, and increasing global regulatory demands Before integrating DrugCard, Biofarm’s PV team faced several key challenges, such as: An extremely high
- [Phibro Case Study: Zero Missed Adverse Events with DrugCard](https://drug-card.io/case-study/phibro-case-study-zero-missed-adverse-events-with-drugcard/) - The story of how Phibro, a global veterinary pharmaceutical company with over 2,000 products in more than 95 countries, streamlined its end-to-end literature monitoring through a fully outsourced DrugCard service. Client: Location:USA Challenge The Real-World Struggles of Veterinary Pharmacovigilance A global veterinary pharmaceutical company faced increasing pressure to manage pharmacovigilance and literature monitoring across eight
- [GM Pharma Case Study: How They Cut Screening Time by 88% with DrugCard](https://drug-card.io/case-study/gm-pharma-case-study-how-they-cut-screening-time-by-88-with-drugcard/) - The story of how a leading multinational pharma automated high-volume literature monitoring with DrugCard’s AI-powered platform Client: Location:Europe Challenge Buried in Data, Facing Compliance Risks Before adopting DrugCard, GM Pharma’s pharmacovigilance team was overwhelmed by unmanageable workloads and compliance pressures. Within just six months, their operations faced: Over 123,000 articles requiring review – a manual
- [Grindex Case Study: 88% Faster PV Screening with DrugCard](https://drug-card.io/case-study/grindex-case-study-88-faster-pv-screening-with-drugcard/) - The story of how international pharmaceutical company Grindex automated safety case detection and scaled its PV program with DrugCard. Client: Location:Latvia Challenge Manual Workload, Missed Insights, and Growing Global Demands Operating across 23 countries with 835 products, Grindex’s pharmacovigilance team faced an unsustainable challenge. Their PV specialists were overwhelmed by time-consuming manual processes that limited
- [Meisys Case Study: Saving 4,300+ Hours on Article Review with DrugCard](https://drug-card.io/case-study/meisys-case-study-saving-4-300-hours-on-article-review-with-drugcard/) - The story of how Meisys, a pharmacovigilance service provider supporting 22 pharmaceutical clients, streamlined literature monitoring with DrugCard. Client: Location:Spain Challenge Managing a Complex PV Portfolio Given its broad and diverse portfolio, Meisys consequently faced several operational challenges: Managing multi-sponsor pharmacovigilance obligations - each with different expectations and timelines. Reviewing over 10,000 literature articles manually.
- [Asphalion Case Study: 94% Faster Article Review with DrugCard](https://drug-card.io/case-study/asphalion-case-study-94-faster-article-review-with-drugcard/) - The story of how Asphalion, a leading scientific and regulatory consultancy operating across 16 countries, managing 124 products and 28 projects throughout Europe, streamlined pharmacovigilance literature monitoring with DrugCard. Client: Location:Spain Challenge Overseeing a PV Portfolio Across Multiple Jurisdictions Overseeing a pharmacovigilance portfolio across multiple jurisdictions came with several significant challenges for Asphalion: First, reviewing

## Categories

- [Uncategorized](https://drug-card.io/blog/category/uncategorized/)
- [Drug Safety](https://drug-card.io/blog/category/drug-safety/) - Drug safety updates for informed choices. Explore on Drug Card.
- [History](https://drug-card.io/blog/category/history/) - Delve into the history of healthcare. Details on Drug Card.
- [Pharmacovigilance](https://drug-card.io/blog/category/pharmacovigilance/) - Pharmacovigilance category updates. Discover on Drug Card.
- [Safety Updates](https://drug-card.io/blog/category/safety-updates/) - Stay updated with safety-related news. Learn on Drug Card.
- [DrugCard](https://drug-card.io/blog/category/drugcard/) - Simplified Medical Literature Monitoring Automation: Streamline the process with Drug Card. Resource overview and updates for efficient workflow
- [Innovations](https://drug-card.io/blog/category/innovations/) - This section of the DrugCard blog will explore the latest technologies transforming the pharma industry, with a focus on innovations in Pharmacovigilance and Regulatory Affairs, including AI/ML, Big Data Analytics, Cloud Computing, and more.

## Tags

- [Audit](https://drug-card.io/blog/tag/audit/) - Audits for quality assurance. Discover on Drug Card.
- [DrugCard](https://drug-card.io/blog/tag/drugcard/)
- [Literature monitoring](https://drug-card.io/blog/tag/literature-monitoring/) - Efficient literature monitoring for healthcare. Explore on Drug Card.
- [Pharmacovigilance](https://drug-card.io/blog/tag/pharmacovigilance/) - The latest news and analysis in the field of pharmacovigilance. Learn more at Drug Card.
- [Abuse](https://drug-card.io/blog/tag/abuse/) - Addressing concerns related to substance abuse. Learn more on Drug Card.
- [Adverse drug reactions](https://drug-card.io/blog/tag/adverse-drug-reactions/) - Understanding adverse drug reactions. Learn more on Drug Card.
- [Antibiotics](https://drug-card.io/blog/tag/antibiotics/) - Antibiotics and their relevance in healthcare. Learn more on Drug Card.
- [Autoinjector](https://drug-card.io/blog/tag/autoinjector/) - Autoinjectors in healthcare: Uses and benefits. Learn more on Drug Card.
- [Capecitabine](https://drug-card.io/blog/tag/capecitabine/) - Capecitabine: Uses and considerations. Discover on Drug Card.
- [Carbamazepine](https://drug-card.io/blog/tag/carbamazepine/) - Carbamazepine: Uses and considerations. Learn more on Drug Card.
- [Ceftriaxone](https://drug-card.io/blog/tag/ceftriaxone/) - Ceftriaxone: Uses and considerations. Explore on Drug Card.
- [Clinical case](https://drug-card.io/blog/tag/clinical-case/) - Clinical cases that offer valuable insights. Learn from Drug Card.
- [Contrast media](https://drug-card.io/blog/tag/contrast-media/) - Explore uses of contrast signals in medical imaging. Discover on Drug Card.
- [COVID-19](https://drug-card.io/blog/tag/covid-19/)
- [DRESS syndrome](https://drug-card.io/blog/tag/dress-syndrome/) - Dress Syndrome: Impact and management. Learn more on Drug Card.
- [Drug Safety](https://drug-card.io/blog/tag/drug-safety/) - Exploring drug safety and pharmacovigilance conference updates. Learn on Drug Card.
- [Drugs](https://drug-card.io/blog/tag/drugs/) - Medicinal properties and uses of drugs. Details on Drug Card.
- [Enalapril](https://drug-card.io/blog/tag/enalapril/) - Enalapril: Uses and considerations in healthcare. Explore on Drug Card.
- [Enoxaparin](https://drug-card.io/blog/tag/enoxaparin/) - Enoxaparin: Understanding its uses and safety. Expert insights on Drug Card.
- [Escitalopram](https://drug-card.io/blog/tag/escitalopram/) - Escitalopram and its applications. Discover on Drug Card.
- [Evolocumab](https://drug-card.io/blog/tag/evolocumab/)
- [Fentanyl](https://drug-card.io/blog/tag/fentanyl/) - Fentanyl and its applications in healthcare. Discover on Drug Card.
- [Furosemide](https://drug-card.io/blog/tag/furosemide/) - Furosemide and its role in healthcare. Expert analysis on Drug Card.
- [Glucocorticosteroids](https://drug-card.io/blog/tag/glucocorticosteroids/) - Understanding glucocorticosteroids in healthcare. Learn more on Drug Card.
- [Hydrochlorothiazide](https://drug-card.io/blog/tag/hydrochlorothiazide/) - Hydrochlorothiazide: Benefits and considerations. Explore on Drug Card.
- [Hydroxychloroquine](https://drug-card.io/blog/tag/hydroxychloroquine/) - Hydroxychloroquine insights and safety. Discover on Drug Card.
- [Inhalation anesthetics](https://drug-card.io/blog/tag/inhalation-anesthetics/) - Inhalation anesthetics: Insights for healthcare professionals. Learn on Drug Card.
- [Investments](https://drug-card.io/blog/tag/investments/) - Investments in healthcare: Exploring opportunities and trends. Learn on Drug Card.
- [Iodixanol](https://drug-card.io/blog/tag/iodixanol/) - Iodixanol in medical imaging: Benefits. Discover on Drug Card.
- [Iohexol](https://drug-card.io/blog/tag/iohexol/) - Iohexol in medical imaging. Learn on Drug Card.
- [Kazakhstan](https://drug-card.io/blog/tag/kazakhstan-en/) - Healthcare insights in Kazakhstan. Learn more on Drug Card.
- [Lamotrigine](https://drug-card.io/blog/tag/lamotrigine/) - Lamotrigine: Uses and safety considerations. Learn more on Drug Card.
- [Levofloxacin](https://drug-card.io/blog/tag/levofloxacin/) - Levofloxacin’s applications in healthcare. Discover on Drug Card.
- [Local medical literature](https://drug-card.io/blog/tag/local-medical-literature/) - Local medical literature resources. Learn more on Drug Card.
- [Medical marijuana](https://drug-card.io/blog/tag/medical-marijuana/) - Medical marijuana insights. Explore on Drug Card.
- [Mesalamine](https://drug-card.io/blog/tag/mesalamine/) - Mesalamine’s role in medicine. Learn on Drug Card.
- [Metformin](https://drug-card.io/blog/tag/metformin-2/) - Metformin in healthcare: Benefits and safety considerations. Expert analysis on Drug Card.
- [Moxifloxacin](https://drug-card.io/blog/tag/moxifloxacin/) - Moxifloxacin in healthcare: Insights and uses. Learn on Drug Card.
- [Nifedipine](https://drug-card.io/blog/tag/nifedipine/) - Nifedipine’s role in healthcare. Learn more on Drug Card.
- [Olanzapine](https://drug-card.io/blog/tag/olanzapine/) - Olanzapine: Benefits and considerations. Learn on Drug Card.
- [Overdose](https://drug-card.io/blog/tag/overdose/) - Overdose prevention: Knowledge and resources. Explore on Drug Card.
- [Paclitaxel](https://drug-card.io/blog/tag/paclitaxel/) - Paclitaxel in medical practice: Insights on Drug Card.
- [Pandemic](https://drug-card.io/blog/tag/pandemic/) - Pandemic insights and healthcare strategies. Discover on Drug Card.
- [Paracetamol](https://drug-card.io/blog/tag/paracetamol/) - Paracetamol in healthcare. Learn more on Drug Card.
- [Patient safety](https://drug-card.io/blog/tag/patient-safety/) - Prioritizing patient safety through vigilant practices. Explore on Drug Card.
- [Piperacillin/tazobactam](https://drug-card.io/blog/tag/piperacillin-tazobactam/) - Piperacillin-tazobactam: Benefits and uses. Explore on Drug Card.
- [Pregnancy](https://drug-card.io/blog/tag/pregnancy/) - Pregnancy-related insights and guidelines. Discover on Drug Card.
- [PSUR](https://drug-card.io/blog/tag/psur/)
- [Reporting](https://drug-card.io/blog/tag/reporting/) - Enhancing safety through reporting mechanisms. Learn more on Drug Card.
- [Safety variations](https://drug-card.io/blog/tag/safety-variations/) - Explore safety variations in pharmaceuticals. Get expert insights on Drug Card.
- [Sevoflurane](https://drug-card.io/blog/tag/sevoflurane/) - Sevoflurane: Its role in anesthesia. Learn more on Drug Card.
- [SmPC update](https://drug-card.io/blog/tag/smpc-update/) - Stay informed with the latest SMPU changes. Details on Drug Card.
- [Special populations](https://drug-card.io/blog/tag/special-populations/) - Special populations’ healthcare considerations. Learn on Drug Card.
- [Stevens-Johnson syndrome](https://drug-card.io/blog/tag/stevens-johnson-syndrome/) - Stevens-Johnson syndrome: Insights and care. Explore on Drug Card.
- [Tamsulosin](https://drug-card.io/blog/tag/tamsulosin/) - Tamsulosin: Benefits and considerations. Explore on Drug Card.
- [Toxic epidermal necrolysis](https://drug-card.io/blog/tag/toxic-epidermal-necrolysis/) - Toxic Epidermal Necrolysis: Understanding and management. Learn more on Drug Card.
- [Vaccine](https://drug-card.io/blog/tag/vaccine/) - Vaccine insights and updates. Details on Drug Card.
- [Vancomycin](https://drug-card.io/blog/tag/vancomycin/) - Vancomycin: Understanding its uses and safety. Expert insights on Drug Card.
- [Warfarin](https://drug-card.io/blog/tag/warfarin/) - Managing warfarin usage for patient safety. Learn more on Drug Card.
- [Pharmacovigilance risk assessment](https://drug-card.io/blog/tag/pharmacovigilance-risk-assessment/) - Risk assessment in pharmacovigilance. Explore on Drug Card.
- [Adverse event reporting](https://drug-card.io/blog/tag/adverse-event-reporting/) - Enhance adverse event reporting in healthcare. Explore on Drug Card.
- [Drug safety recall](https://drug-card.io/blog/tag/drug-safety-recall/) - Drug safety recall implications. Discover on Drug Card.
- [eye drops](https://drug-card.io/blog/tag/eye-drops/) - Eye drops: Understanding their uses and safety. Learn on Drug Card.
- [Dermal fillers](https://drug-card.io/blog/tag/dermal-fillers/) - Dermal fillers: Cosmetic considerations. Explore on Drug Card.
- [Safety signals](https://drug-card.io/blog/tag/safety-signals/) - Stay alert to safety signals. Explore on Drug Card.
- [Pharmacovigilance events](https://drug-card.io/blog/tag/pharmacovigilance-events/) - Pharmacovigilance events: Insights and updates. Discover on Drug Card.
- [Pediatric pharmacovigilance](https://drug-card.io/blog/tag/pediatric-pharmacovigilance/)
- [Ibuprofen](https://drug-card.io/blog/tag/ibuprofen/)
- [Fixed drug eruptions](https://drug-card.io/blog/tag/fixed-drug-eruptions/)
- [Excipients](https://drug-card.io/blog/tag/excipients/)
- [Veterinary pharmacovigilance](https://drug-card.io/blog/tag/veterinary-pharmacovigilance/)
- [Individual Case Safety Reports](https://drug-card.io/blog/tag/individual-case-safety-reports/)
- [Herbal medicine](https://drug-card.io/blog/tag/herbal-medicine/)
- [Aloe vera](https://drug-card.io/blog/tag/aloe-vera/)
- [Aspirin](https://drug-card.io/blog/tag/aspirin/)
- [Thalidomide](https://drug-card.io/blog/tag/thalidomide/)
- [Drug repurposing](https://drug-card.io/blog/tag/drug-repurposing/)
- [Pharmacovigilance data](https://drug-card.io/blog/tag/pharmacovigilance-data/)
- [Nasal drops](https://drug-card.io/blog/tag/nasal-drops/)
- [Antimicrobial resistance](https://drug-card.io/blog/tag/antimicrobial-resistance/)
- [Azithromycin](https://drug-card.io/blog/tag/azithromycin/)
- [Drug packaging](https://drug-card.io/blog/tag/drug-packaging/)
- [Gambling behavior](https://drug-card.io/blog/tag/gambling-behavior/)
- [Pramipexole](https://drug-card.io/blog/tag/pramipexole/)
- [Aripiprazole](https://drug-card.io/blog/tag/aripiprazole/)
- [Amoxicillin-clavulanic acid](https://drug-card.io/blog/tag/amoxicillin-clavulanic-acid/)
- [Propranolol](https://drug-card.io/blog/tag/propranolol/)
- [Infantile hemangioma](https://drug-card.io/blog/tag/infantile-hemangioma/)
- [FDA](https://drug-card.io/blog/tag/fda/)
- [TGA](https://drug-card.io/blog/tag/tga/)
- [Medsafe](https://drug-card.io/blog/tag/medsafe/)
- [Day 0](https://drug-card.io/blog/tag/day-0/)
- [Prescription Symmetry Sequence Analysis](https://drug-card.io/blog/tag/prescription-symmetry-sequence-analysis/)
- [NSAID](https://drug-card.io/blog/tag/nsaid/)
- [Medication errors](https://drug-card.io/blog/tag/medication-errors/)
- [Male fertility](https://drug-card.io/blog/tag/male-fertility/)
- [EMA](https://drug-card.io/blog/tag/ema/)
- [High-Alert Medications](https://drug-card.io/blog/tag/high-alert-medications/)
- [Semaglutide](https://drug-card.io/blog/tag/semaglutide/)
- [PubMed](https://drug-card.io/blog/tag/pubmed/)
- [Minoxidil](https://drug-card.io/blog/tag/minoxidil/)
- [Dietary supplements](https://drug-card.io/blog/tag/dietary-supplements/)
- [Pseudoephedrine](https://drug-card.io/blog/tag/pseudoephedrine/)
- [Polypharmacy](https://drug-card.io/blog/tag/polypharmacy/)
- [MedSafetyWeek](https://drug-card.io/blog/tag/medsafetyweek/)
- [Silicone](https://drug-card.io/blog/tag/silicone/)
- [Long QT Syndrome](https://drug-card.io/blog/tag/long-qt-syndrome/)
- [Off-label use](https://drug-card.io/blog/tag/off-label-use/)
- [Administration errors](https://drug-card.io/blog/tag/administration-errors/)
- [Vanessa's Law](https://drug-card.io/blog/tag/vanessas-law/)
- [Metamizole](https://drug-card.io/blog/tag/metamizole/)
- [Probiotics](https://drug-card.io/blog/tag/probiotics/)
- [Risk Minimisation Measures](https://drug-card.io/blog/tag/risk-minimisation-measures/)
- [Drug-Induced Oral Reaction](https://drug-card.io/blog/tag/drug-induced-oral-reaction/)
- [Drug-Drug Interactions](https://drug-card.io/blog/tag/drug-drug-interactions/)
- [GLP-1 Agonists](https://drug-card.io/blog/tag/glp-1-agonists/)
- [Vitamin B12 deficiency](https://drug-card.io/blog/tag/vitamin-b12-deficiency/)
- [COVID-19 vaccine](https://drug-card.io/blog/tag/covid-19-vaccine/)
- [Drug Class Effect](https://drug-card.io/blog/tag/drug-class-effect/)
- [Medicine shortages](https://drug-card.io/blog/tag/medicine-shortages/)
- [Pharmacovigilance documents](https://drug-card.io/blog/tag/pharmacovigilance-documents/)
- [Homeopathic medicines](https://drug-card.io/blog/tag/homeopathic-medicines/) - Homeopathic medicines
- [Addendum to the Clinical Overview](https://drug-card.io/blog/tag/addendum-to-the-clinical-overview/) - Addendum to the Clinical Overview
- [Nocebo effect](https://drug-card.io/blog/tag/nocebo-effect/) - Nocebo effect
- [Drug discontinuation](https://drug-card.io/blog/tag/drug-discontinuation/) - Drug discontinuation
- [Precautionary measures](https://drug-card.io/blog/tag/precautionary-measures/) - Precautionary measures
- [Drug infusion rate](https://drug-card.io/blog/tag/drug-infusion-rate/) - Drug infusion rate
- [Good pharmacovigilance practices (GVP)](https://drug-card.io/blog/tag/good-pharmacovigilance-practices-gvp/) - Good pharmacovigilance practices (GVP)
- [Contact Lens](https://drug-card.io/blog/tag/contact-lens/) - Contact Lens
- [Pharmacovigilance terminology](https://drug-card.io/blog/tag/pharmacovigilance-terminology/) - Pharmacovigilance terminology
- [Specific Adverse Reaction Follow-up Questionnaire](https://drug-card.io/blog/tag/specific-adverse-reaction-follow-up-questionnaire/) - Specific Adverse Reaction Follow-up Questionnaire
- [Drug safety database](https://drug-card.io/blog/tag/drug-safety-database/) - Drug safety database
- [AI in Pharmacovigilance](https://drug-card.io/blog/tag/ai-in-pharmacovigilance/) - AI in Pharmacovigilance
- [Orphan Drugs](https://drug-card.io/blog/tag/orphan-drugs/) - Orphan Drugs
- [World AMR Awareness Week](https://drug-card.io/blog/tag/world-amr-awareness-week/) - World AMR Awareness Week
- [Cannabis](https://drug-card.io/blog/tag/cannabis/) - Cannabis
- [Nasal decongestants](https://drug-card.io/blog/tag/nasal-decongestants/) - Nasal decongestants
- [Real-World Evidence](https://drug-card.io/blog/tag/real-world-evidence/) - Real-World Evidence